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ABSTRACT
Estimating Treatment Effects and Identifying Optimal Treatment Regimes to
Prolong Patient Survival
by
Jincheng Shen
Co-Chairs: Professor Jeremy M. G. Taylor and Assistant Professor Lu Wang
Motivated by an observational prostate cancer recurrence study, we investigate the
effect of treatment on survival outcome. For studies such as these, it is important
to properly handle the confounding effects, especially from longitudinal covariates.
In addition, baseline covariates may also reflect the heterogeneity of the population
in responding to the treatment. It is possible to recognize these differences and cus-
tomize the treatment strategy accordingly.
In the first project, we formulate a generalized accelerated failure time (AFT) model
to describe the treatment effect and the model includes a longitudinal covariate as
a functional predictor, whose coefficient is a time-varying nonparametric function.
We propose a spline-based sieve estimation for the time-varying coefficient of the
functional predictor, and maximize the likelihood in the sieve space where we ap-
proximate the functional predictor and nonparametric coefficient using a B-spline
basis. Under certain regularity conditions, the proposed estimator is consistent and
semi-parametrically efficient. Simulation studies are conducted to demonstrate the
xi
potential use of the proposed method to estimate the effect of a treatment assigned
at baseline under various time-dependent confounding mechanisms.
We further consider the interaction between treatment and other covariates, and
explore the heterogeneity of the treatment effect and approaches to personalize the
treatment assignment to optimize the survival outcome. In the second project, using
the causal inference framework, we consider the counterfactual outcome as if every
patient follows a given treatment regimen and develop a method to identify the opti-
mal dynamic treatment regime from observational longitudinal data. We propose to
use Random Forest to model the regime adherence of each subject, and use inverse
probability weights to adjust for non-adherence to obtain the regime specific survival
distribution. The proposed estimator is consistent, and its finite sample performance
is assessed through simulation studies.
In the third project, we consider the optimal treatment regime based on available
baseline covariates in a target population. The available data to estimate the optimal
regime is an observational study that includes these and some additional baseline
covariates. Instead of optimizing over a pre-defined class of regimes as in Project
2, we consider a more general class of candidate regimes through flexible models of
the outcomes. We propose to use Random Survival Forest plus an inverse probabil-
ity weighted bootstrap to estimate the causal outcomes while marginalizing over the
covariates that may not be of primary interest. By comparing the restricted mean
survival times, the optimal regime can be estimated for the target population. We
evaluate the performance of the proposed method through simulation studies, and
demonstrate its advantage compared to some traditional approaches.
xii
CHAPTER I
Introduction
Prostate cancer is the most commonly diagnosed cancers among American men
(Siegel et al., 2013). Often, after initial treatment, patients diagnosed with clini-
cally localized prostate cancer are actively monitored for elevated and/or rising levels
of prostate-specific antigen (PSA). The typical pattern of PSA after initial radia-
tion therapy is well known and associated with some of the pre-treatment variables
(Proust-Lima et al., 2008). It decreases in everyone for about a year and then may
never show a subsequent increase; if it does rise, it increases approximately expo-
nentially with time. Figure 1.1 shows a typical trajectory of log(PSA+0.1). Rising
values of PSA are indicative of an increased risk for the clinical recurrence of prostate
cancer (Zagars and von Eschenbach, 1993). In these cases, patients sometimes re-
ceive additional new treatment (called salvage therapy) in order to prevent or delay
recurrence. Figure 1.2 shows the four types of possible sequences of salvage therapy
and recurrence. One such salvage therapy treatment is androgen deprivation therapy
(ADT). Although salvage ADT is generally thought to be beneficial in delaying the
recurrence of prostate cancer, the magnitude of this benefit is not well quantified.
Complicated confounding is involved between the salvage treatment which is given by
indication, and the time to recurrence, which is a survival type of outcome. Elevated
1
and/or rising PSA levels are a risk factor for recurrence of prostate cancer but are
also a predictor of treatment by salvage ADT (SADT), thus PSA and slope of PSA
are (time-dependent) confounders in the relation between salvage ADT and prostate
cancer recurrence. In general, this type of a relation between a time-dependent con-
founder and a time-varying treatment is typically present whenever there is “treat-
ment by indication” (Robins , 1989a). Correctly estimating the effect of the time-
dependent salvage treatment and the impact from the longitudinal covariates is of
great importance for clinical practice. Along this line, Kennedy et al. (2010) focused
on a multi-center prostate cancer recurrence study with prostate cancer patients who
were initially treated with external beam radiation therapy (EBRT). Patients came
from four cohorts: University of Michigan (Michigan, U.S.A.), Radiation Therapy On-
cology Group, Peter MacCallum Cancer Centre (Melbourne, Australia), and William
Beaumont Hospital (Michigan, U.S.A.). Patients were closely monitored for possible
recurrence. Their PSA values were recorded at regular visits along with other clinical
characteristics. Salvage ADT treatment was given to some of the patients to reduce
the risk of cancer recurrence. More details of the dataset can be found in Chapter III
or Proust-Lima et al. (2008); Kennedy et al. (2010). Kennedy et al. (2010) proposed
two methods to estimate the treatment effect conditional on the other covariates, es-
pecially the time-dependent PSA. Two-stage method fits the longitudinal model for
PSA in the first step and then estimates the treatment effect from a Cox model. The
other method, so-called Sequential Stratification, constructs time-dependent stratum
for each patient undergoing SADT to mimic a sequence of conditionally randomized
SADT assignments. A stratified Cox model is fitted to obtain the estimation of the
treatment effect. Taylor et al. (2013) further evaluated the performance of these
methods and compared them with marginal structural models (MSMs) under inverse
probability weighting (IPW) through series of simulation studies. The relationship
between the subject specific treatment effect and the marginal treatment effect was
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also investigated.
In Chapter II, we investigate the potential impact of PSA history on the current
risk of recurrence. We consider a situation with a time-dependent covariate (such as
PSA) and a time-independent covariate of interest, which could be treatment group
indicator, while the PSA is considered as a potential predictor. The Cox proportional
hazard model is the most frequently used and well-recognized approach in modeling
time to event outcomes. The Cox model can incorporate both time-independent and
time-dependent covariates. However, its proportional hazard assumption may limit
its application in some situations. The accelerated failure time (AFT) model is an
appealing alternative that can naturally incorporate the continuous impact of time
dependent predictors. Furthermore, the coefficient for the time-independent covari-
ate in an AFT model is quantified in a straightforward way. For example, hormone
therapy is often thought of as delaying the prostate cancer recurrence by stretching
the time scale with a multiplying factor. If we consider the baseline covariate to be an
indicator of assigning patients to either hormone therapy or control group, then the
AFT model will provide the desired summary measure for the treatment effect, and
it can also handle the entire PSA history in a natural way. Thus we consider an AFT
model where the coefficients for the time-dependent covariates may be time-varying.
To obtain an unbiased estimator for the coefficients for the baseline covariates (e.g.
the treatment effect for hormone therapy), we propose a spline-based efficient estima-
tion procedure, and maximize the likelihood in the sieve space where we approximate
the functional predictor and nonparametric coefficient using a B-spline basis. Asymp-
totic properties of the proposed estimator are developed. We derive the convergence
rate for the sieve estimator of the nonparametric coefficient of the functional predic-
tor, and establish
√
n-consistency of the regression coefficients of the parametric part,
such as the treatment effect.
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However, in practice the therapy may not be given at baseline, and it may be of
more interest to know what would be the best time to initiate hormone therapy
based on the patient’s specific clinical history, so that therapy can be tailored for
each patient. For example, guidelines such as “give SADT when PSA first goes above
4 ng/ml if age is less than 75” would be very useful to physicians and health care
providers in the management of prostate cancer recurrence. The major challenges to
provide such detailed guidelines are (i) it is very expensive to run a randomized trial
to cover all possible treatment plans of interest; (ii) in observational studies, it is a
problem on how to use the data efficiently as the “optimal treatment regime” would
only have been followed by a very small subgroup of the whole dataset; (iii) in order
to compare the treatment effect between groups with different treatment regimes in
observational data, we need to correctly account for the artificial treatment effect,
which arise, for example, because groups of patients with lower PSA levels tends to
have delayed recurrences even without treatment.
Thus, in Chapter III, we investigate this question of identifying the optimal dy-
namic treatment regime from observational data employing techniques from causal
inference. We extend the marginal structural model method to estimate the survival
distribution for different counterfactual treatment regimes. The challenges come from
the weight estimation which are derived from the model for the observed treatment
assignment mechanism. These weights are needed at multiple time points for each
patient in the marginal structural model methodology. Logistic models which are lin-
ear in the covariates X are frequently employed for this purpose (Herna´n et al., 2006;
Zhang et al., 2013). This may not always provide a satisfactory approximation as the
underlying treatment mechanism varies from case to case, and a more sophisticated
dependency may exist between the actual treatment assignment and the covariates.
We propose to use Random Forests to model the treatment assignment mechanism
4
and estimate the time-dependent weights. The restricted mean survival time (RMST)
is also employed to enable the comparison among various regimes and serves as the
objective function in the optimization process.
Another issue in personalizing the treatment regime relates to the modeling of the out-
comes. Identifying the optimal regime always involves some maximization/minimization
of some summary statistics of the outcome. The optimization thus depends on the
model assumption for the outcome, which is equivalent to performing the optimiza-
tion within a pre-specified class of regimes. It is important that the outcome model
matches the truth, or there could be bias for the final regime that is identified. For
example, consider a randomized trial with a scalar covariate X ∼ Uniform(−1, 1),
and A is the treatment indicator which takes value 1 if the patient is assigned to
treatment group and 0 for being assigned to the control group, with P (A = 1) = 0.5.
Consider a proportional hazard model for the outcome of the following form:
λ(t) = λ0 exp
(
ax2 − ax+ 1
4
a
)
= λ0 exp
{
a
(
x− 1
2
)2}
with baseline hazard λ0 = 0.2. If we do not consider censoring, then the true optimal
regime will be gopt0 (X) ≡ 0, i.e. always not giving treatment. However, if we fit the
survival time with a Cox model using the following structure:
λ(t) = λ0(t) exp (β1x+ β2a+ β3ax)
= λ0(t) exp {β1x+ (β2 + β3x) a} ,
and consider treatment regimes in the form of G = {g(X) = I(β2 +β3X < 0), β2, β3 ∈
R}, for −1 ≤ X ≤ 1. It is easy to see that gopt ∈ G, however, as we generate data
5
for a cohort of n = 1000 patients with 1000 replicates, we get the average estimates
from Cox model as βˆ2 = 0.53 and βˆ3 = −1.00, the estimated optimal regime would
be gˆopt(X) = I(0.53−1.00X < 0) = I(X > 0.53), which is clearly different than gopt.
Thus, even if the true optimal regime is in the considered regime space, the algorithm
may pick a different one when the regime space under consideration mismatches the
structure of the true outcome model. One possible solution here is to assume a
model with enough flexibility, and then apply machine learning techniques to provide
promising alternatives for this purpose. In Chapter IV, we propose to employ the
Random Survival Forest (RSF) method to tackle this issue. As the treatment model
is not the major concern in this case, we consider the situation where all the covariates
W = (XT ,ZT ) are measured at baseline (pretreatment), and the treatment A is also
assigned at baseline. Again, we consider the scenario of observational data, where W
is associated with both the treatment and the survival outcome. Although X and
Z may be highly correlated, the availability of Z is not guaranteed in the general
population due to various reasons, so the optimal regime of interest need to be a
series of generalizable treatment rules and need to be based on X only. We propose
to use inverse probability weighting technique to account for the possible selection
bias. By conducting a weighted bootstrap with Random Survival Forest, we are able
to correctly model the counterfactual survival outcomes using observational data and
identify the optimal treatment regime as the one which maximizes the restricted
mean counterfactual survival time. We conclude the dissertation in Chapter V with
a discussion of future work and related open problems.
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Figure 1.1: Typical log(PSA) Patterns
Figure 1.2: Structure of Longitudinal, Treatment, and Recurrence Data.
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CHAPTER II
Efficient Estimation of the Treatment Effect Under
the Impact of the Entire PSA History
The accelerated failure time (AFT) model is an approach that can be used to
assess the continuous impact of time-dependent predictors in time-to-event analyses,
where the effect of a baseline covariate can be quantified in a straightforward way. For
example, the AFT model with an indicator of hormone therapy provides the desired
summary measure for the treatment effect, which is often thought of as delaying
prostate cancer recurrence by stretching the time scale with a multiplying factor. In
this chapter, we consider an AFT model with both time-dependent covariates X(t)
and time-independent covariates Z. This model can handle the entire history of a
longitudinal variable PSA as a functional predictor, and the coefficients for X(t) in
our model are allowed to vary with time as well. We propose a spline-based sieve
estimation of the time-varying coefficient of the functional predictor, and maximize
the likelihood in the sieve space where we approximate the functional predictor and
nonparametric coefficient using B-spline basis. The proposed estimator is proved to
be asymptotically consistent, and the regression coefficients of the parametric part,
such as treatment effect, is shown to be
√
n-consistent.
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2.1 Introduction
In cancer research, it is often of primary interest to understand the association
between a risk factor or a certain treatment with the patients’ survival outcome. In
many situations one big challenge is how to correctly adjust for the time-varying
confounding variables. For example, in prostate cancer, PSA is a very important
time-varying biomarker for disease progression, and is believed to be highly associ-
ated with the hazard of cancer recurrence. One would expect such a biomarker to
have a continuous impact over the course of disease development, because as the
disease progress to a different point, PSA may indicate a different level of cancer
recurrence risk. In fact, the whole history of PSA plays an important prognostic role
besides the point-wise health status of a prostate cancer patient. For instance, it is
likely that two patients with different PSA trajectories respond very differently to
the same therapy, even though their current PSA values are the same. Therefore,
how to adjust for the longitudinal confounding effect of the whole PSA trajectory or
PSA changes while evaluating the association of other baseline covariates, such as the
treatment effect of hormone therapy on patient recurrence risk becomes complicated.
In this chapter, we are proposing a semiparametric modeling approach to allow for
more flexibility.
Statistical tools have been developed to study the cumulative effects of longitudi-
nal factors, especially for studies with continuous or categorical outcomes (Xia and
Tong , 2006; Kong , 2010). When the outcome is a time to event, the proportional
hazards model (Cox , 1972, 1975) is the most frequently used approach in practice,
due to the availability of efficient estimation procedures that are implemented in all
statistical software packages. However, in order to obtain valid statistical inferences,
these models require the proportional hazard assumption, which is quite strong for
many practical applications and can be easily violated when there are continuous im-
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pacts from time-varying predictors. Although the proportional hazard model can be
extended by incorporating time-varying coefficients (Murphy and Sen, 1991), the sta-
tistical inference involves histogram-sieve estimation on the partial likelihood. Chen
and Zhou (2007) proposed a local partial likelihood approach to directly estimate
the relative risk function. The time-varying proportional hazard ratio assumption
may not have a straightforward interpretation. On the other hand, the accelerated
failure time (AFT) model (Kalbfleisch and Prentice, 2011), which directly relates the
monotonically transformed survival time to the covariates of interests, is “in many
ways more appealing because of its quite direct physical interpretation” (Reid , 1994)
and thus frequently serves as an attractive alternative to the Cox proportional haz-
ards model. Suppose the covariate vector is W , then a common AFT model for the
survival outcome T takes the log-linear form
log T = −W Tγ +  (2.1)
where  is measurement error, which is assumed to have a particular distribution
independent of W . As in the cancer example, where T is the recurrence free survival
time and one dimensional W is the treatment, then γ, the treatment effect estimated
from model (2.1), would have a more straightforward interpretation as a multiplica-
tive factor to accelerate or decelerate the disease course to cancer recurrence.
There has been a plethora of literature on both theoretical development and ap-
plications of AFT models. Log-normal model is one of the most popular parametric
AFT models and has been used in a wide range of applications (Royston, 2001; Long-
ford , 2009; Ko¨hler and Kowalski , 2012; Chapman et al., 2013). To relax the fully
parametric restriction, semi-parametric AFT models has also been intensively stud-
ied. Prentice (1978) proposed the rank estimator for the baseline hazard function
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based on the well-known weighted log-rank statistics, and soon after that, Buckley
and James (1979) introduced a modified version of least-squares estimator to account
for the censoring. Following this initial work, extensive theoretical development and
extensions have been done (Ritov , 1990; Tsiatis , 1990; Lai and Ying , 1991; Ying ,
1993; Jin et al., 2003, 2006). Ritov and Wellner (1988) derived the semiparametric
efficient score functions for the slope parameters in the linear regression model, which
involves the derivative of the baseline hazard function (i.e., density of ). Zhang et al.
(2009) proposed to use monotone B-spline when there is interval censoring, and Ding
and Nan (2011) employed a spline-based method when the parameters are bundled
together. Zeng and Lin (2007) considered a more general setting, where W could
be time-dependent, and proposed a kernel smoothing based efficient estimation pro-
cedure, but they restrict the effect of W to be constant, and the kernel smoothing
procedure may not be straightforward to implement in biomedical studies. In prac-
tice, it may be more realistic to assume that the impact of a time-dependent covariate
also varies with time. In this chapter, we consider a more general setting where W is
a vector which contains both time-dependent covariates X(t) and time-independent
covariates Z, and the coefficients for X(t) could also vary with time. Specifically, we
consider the following model
e =
T∫
0
exp{X(u)β(u) +Zγ}du (2.2)
where  is the error term similar as in model (2.1). Unlike Zeng and Lin (2007),
our model specification in (2.2) allows the impact of PSA to vary over time, which
represent a more realistic situation. For example, it is possible that the patient’s
PSA history within the last year would have more impact on his current health sta-
tus than his PSA levels three years ago. In model (2.2), we also consider a baseline
covariate, for example, the hormone therapy which is assigned to the patient at time
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zero. We assume a parametric baseline hazard using a lognormal distribution. We
propose a new approach by directly maximizing the log likelihood function in a sieve
space, where the time-varying coefficients are approximated by B-splines. A resam-
pling procedure is developed for the variance estimation. In addition, we investigate
the asymptotic consistency and efficiency of the proposed estimators using empirical
process theory.
The rest of the chapter is organized as follows. In Section 2.2, we introduce the
notation and specify the structure for our AFT model. In Section 2.3 we propose
the sieve estimator for both the time-varying and fixed coefficients. We investigate
the asymptotic properties of our new estimators in Section 2.4, followed by compre-
hensive simulation studies presented in Section 2.5. Finally, we conclude with a brief
discussion and propose some potential extensions in Section 2.6. Technical details are
included in Section 2.7.
2.2 Notation and Model Specification
We consider a cohort of n patients. For patient i, let Ti denote the failure time
and Ci denote the censoring time for subject i, where i = 1, · · · , n. Define Yi =
min(Ti, Ci) and ∆i = I(Ti ≤ Ci). We assume that Ci is independent of Ti, conditional
on covariates W i = {X i(·),Zi}, To make the presentation easier, without loss of
generality, we only consider the case when both X i(·) and Zi are one-dimensional,
throughout denoted as Xi(·) and Zi respectively. Then the likelihood for a single
observation of (Y,∆,W ) of model (2.2) is
LY,∆,W (y, δ,w) = λT |W (y))δ exp{−ΛT |W (y)}H(y, δ,w),
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where λT |W (t) and ΛT |W (t) denote the conditional hazard and cumulative hazard
functions of T given and W . H(y, δ,w) includes both the conditional distribution
of C given W = (X(·), Z) and the marginal distribution of X and Z. We assume
that H is free of λ, β and γ, so we ignore H from the likelihood function. We further
assume a lognormal distribution with i ∼ N(0, σ2). The log-likelihood for single
observation (Y,∆,W ) becomes:
l(β, γ, σ) =∆{β(Y )X(Y )} −∆R(Y ; β)−∆ log σ
+ ∆ log φ
(
R(Y ; β) + γZ
σ
)
+ (1−∆) log Φ
(
−R(Y ; β) + γZ
σ
)
,
where Φ(·) and φ(·) are the cdf and pdf of the standard normal distribution, and
R(Y ; β) = log
∫ Y
0
eβ(u)X(u)du. Notice that the way we set up model (2.2) makes the
current hazard depends on the current value of X(·), but also the history of X(·) up
to the current time, i.e.
λT |W (t|w) = λT |X(t),Z(t|x(t), z)
= φ
(
r(t; β) + γz
σ
)
/
{
σer(t;β)+γz · Φ
(
r(t; β) + γz
σ
)}
,
for t ∈ (0,∞), where x(t) = {x(u) : 0 < u ≤ t} is the observed history for X(·) up to
time t, r(t; β) = log
∫ t
0
eβ(u)x(u)du is the realization of R(t; β) which depends on x(t).
2.3 The Estimating Procedure
2.3.1 Spline Based Estimation
In order to perform estimation, we propose to use the spline-base sieve maximum
likelihood estimation for Model (2.2). Spline techniques have been extensively used as
an effective tool for dimension reduction in nonparametric estimation. Stone (1985,
1986) has proved in theory that a smooth unknown function can be well approximated
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using a spline. Some further convergence results of spline-based sieve estimates have
been developed by Shen and Wong (1994). Under the regularity conditions (C1)-
(C3) stated in Section 2.4, let (0, a] be an interval of interest, where 0 < a <∞. Let
0 < t1 < · · · < tKn < tKn+1 = b be a partition of (0, a] withKn subintervals I0 = (0, t1)
and Ij = [tj, tj+1), j = 1, · · · , Kn − 1 and IKn = [tKn , tKn+1], with Kn = O(nν) and
max1≤j≤Kn+1 |tj − tj−1| = O(n−ν) for some positive number ν ∈ (0, 1/2). Denote
the set of partition points by TKn = {t1, · · · , tKn}. Following Schumaker (1981),
Definition 4.1, let Sn(TKn , Kn, p) be the space of polynomial splines of order p ≥ 1
consisting of function s satisfying (i) the restriction of s to Ij is a polynomial of order
p (or equivalently, of degree p − 1) for p ≤ Kn; (ii) for p ≥ 2 and 0 ≤ p′ ≤ p − 2, s
is p′ times continuously differentiable on [a, b]. According to Schumaker (Schumaker
(1981), Corollary 4.10), there exists a set of B-spline basis functions {Bj, 1 ≤ j ≤ qn}
with qn = Kn + p such that for any s ∈ Sn(TKn , Kn, p), we can write
s(t) =
qn∑
j=1
ωjBj(t), (2.3)
where following Shen and Wong (1994) we require maxj=1,··· ,qn |ωj| ≤ cn and cn is
allowed to grow with n slowly enough. Let ω = {ω1, · · · , ωqn} be the collection of all
the coefficients in the representation (2.3). Under suitable smoothness assumptions,
the true parameter β0(·) can be well approximated by some function in Sn(TKn , Kn, p).
2.3.2 Likelihood Approximation
Our goal is to seek a member of Sn(TKn , Kn, p) together with a value of γ ∈ Γ and
a value of σ ∈ Σ that maximizes the log likelihood function. Specifically, let (γˆn, σˆn)
be the value that maximizes
ln(ω, γ, σ) = n
−1
n∑
i=1
[
∆i
{
qn∑
j=1
ωjBj(Yi)Xi(Yi) + γZi
}
+ ∆i log λ(e
Q∗i (ω,γ))− Λ(eQ∗i (ω,γ))
]
,
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where
Q∗i (ω, γ) = log
Yi∫
0
exp
{
qn∑
j=1
ωjBj(Yi)Xi(Yi) + γZi
}
du,
and σ is a parameter in λ(·) and Λ(·). This then becomes a sieve maximum likelihood
estimation problem where the unknown function in the log likelihood is approximated
by a linear span of some known basis functions to form a sieve log likelihood. Following
Geman and Hwang (1982), we can maximize the sieve log likelihood with respect to
the unknown coefficients in the linear span to obtain a sieve maximum likelihood
estimator. This will significantly reduces the dimensionality of the maximization
since the number of basis functions needed to approximate the unknown function
grows at a much slower rate as the sample size increases. Here the maximization can
be solved by standard methods for the accelerated failure time model with parametric
baseline hazards. We use R function aftreg() from eha package to fit for (γˆn, σˆn) and
ωˆ. Then the time-varying coefficient can be estimated as βˆ(t) =
∑qn
j=1 ωˆjBj(t).
2.4 Asymptotic Theory
In this section, we investigate the asymptotic properties of the proposed estimator.
To obtain the consistency of γˆn and βˆ(t), and the asymptotic normality result for γˆn,
we need to impose the following regularity conditions:
(C1) Xi(t) is bounded for t ∈ R+, i.e. ∀t, ∃C s.t. P(‖Xi(t)‖ ≤ C) = 1;
(C2) σ ∈ Σ, where Σ is a compact subset of R+. We assume there exists a small
κ > 0, s.t. σ > κ;
(C3) γ ∈ Γ, where Γ is a compact subset of R−. We assume there exist a large
M > 0, s.t. −M < γ ≤ 0;
(C4) ∀t, ∃C s.t. P(0 ≤ ‖β(t)Xi(t)‖ ≤ C) = 1;
(C5) Let B denote the collection of bounded functions β on (0, a] with bounded
derivatives β(j), j = 1, · · · , k, and we assume that the kth derivative β(k) satisfies the
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following Lipschitz continuity condition:
∣∣β(k)(s)− β(k)(t)∣∣ ≤ L |s− t|m for s, t ∈ (0, a]
where k is a positive integer and m ∈ (0, 1] such that p = k + m ≥ 3, and L <∞ is
an unknown constant. The true weight β0 ∈ Bp.
Condition (C1)-(C4) are common regularity assumptions that have been imposed
in the literature for similar problems (Zhang et al., 2009), while conditions (C5) is
assumed here to provide desirable controls of the spline approximation error rates of
the first and second derivatives of β0. We can see in the following theorems that these
conditions are sufficient to guarantee our estimator θˆn = (βˆn, γˆn, σˆn) to be asymptotic
consistent.
Theorem 2.1. Let Kn = O(n
ν), where ν satisfies the restriction 1
2(1+p)
< ν < 1
2p
with p being the smoothness parameter defined in Condition (C5). Suppose Condition
(C1)-(C5) hold and the failure time T follows Model (2.2), then
d(θˆn,θ0) = Op
[
n−min{pν,(1−ν)/2}
]
,
where θ = {β(·), γ, σ} is the vector of parameters, d(θ1,θ2) = {||β2 − β1||2Y + |γ2 −
γ1|2 + |σ2 − σ1|2}1/2 and we define ‖β2 − β1‖Y =
∫ Y
0
|β2(u)− β1(u)| du.
Theorem 2.1 establishes the consistency of our proposed estimators. But βˆn(·) con-
verges to the true β0(·) in a slower rate compared to γˆn and σˆn. With a non-parametric
estimator βˆn(·), one would be interested to see whether that will affect the parametric
convergence rate of γˆn. In Theorem 2.2, we show the asymptotic normality for our
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proposed estimator γˆn, and also develop the estimation efficiency bound.
Theorem 2.2. Under Model (2.2), the efficient score function of estimating γ is:
l˙∗γ(β, γ, σ) =
∫ Y
0
{Z − h∗(u)X(u)}eβ(u)X(u)du∫ Y
0
eβ(u)X(u)du
× 1
σ
{
∆
φ(1)({R(Y ; β0) + γZ} /σ)
φ({R(Y ; β0) + γZ} /σ) − (1−∆)
φ({R(Y ; β0) + γZ} /σ)
1− Φ({R(Y ; β0) + γZ} /σ)
}
,
with h∗(u) =
EY˜ ,∆˜,W˜ {Z˜X˜(Y˜ )|R˜ = log
∫ t
0
eβ(u)X(u)du, ∆˜ = 1}
EY˜ ,∆˜,W˜ {X˜2(Y˜ )|R˜ = log
∫ t
0
eβ(u)X(u)du, ∆˜ = 1}
Notice here φ(1)(·) is the first derivative of φ(·). Suppose that the conditions in
Theorem 2.1 hold and I(γ0) = E
{
l∗γ0(Y,∆, Z)
⊗2} is nonsingular, we have
√
n(γˆn − γ0) d−→ N(0, I−1(γ0))
Theorem 2.2 shows that as n → ∞, if we properly control the increasing rate of
Kn, our proposed estimator for γ0, γˆn, can achieve the
√
n-consistency. In fact, the
proposed estimating procedure can provide efficient estimation of γ0, which means the
asymptotic variance of γˆn achieves the efficiency bound under Model (2.2), I
−1(γ0) =[
E
{
l∗γ0(Y,∆,W )
⊗2}]−1. More detials of the proof of these theorems are given in the
Appendix, as well as the development of the efficient score function to estimate γ.
2.5 Simulation Study
Simulation studies are carried out to evaluate the finite sample performance of the
proposed method. Data are generated as follows: for each subject, we independently
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generate (Yi,∆i, Xi(·), Zi), where the treatment-free longitudinal covariate
Xi(t) = (α0 + ai0) + (α1 + ai1)t, (2.4)
(α0, α1) are fixed effect parameters, and (ai0, ai1) are subject-specific random effects.
We assume the longitudinal covariate (e.g.,PSA in the case of prostate cancer) is lin-
ear over time, and the random effects (ai0, ai1) ∼ MVN(0,Σ).
The time-independent covariate Zi is generated from Zi ∼ Bernoulli(p). Given the
trajectory of Xi(t) and Zi, we generate the survival time according to a log-normal
distribution
ei =
Ti∫
0
exp [β(u)Xi(u) + γZi] du, (2.5)
where i ∼ N(0, σ2), γ is the treatment effect, the true values of these parameters
are as following:
α0 = −0.5, α1 = −0.3,Σ =
1.0 0.5
0.5 0.25
 , γ = −2.0.
β(t) is the weight for Xi(t), for t ∈ [0, K], where K is the longest follow-up time under
investigation and we consider three different scenarios with different β(t) functions:
(I) β(t) = 0.6 ·g(t/K) where g(x) is the density function of Beta(3,3) distribution, i.e.
g ∼ Beta(3, 3). This reflects the situation where the weight β(t) is symmetric over
t = K/2 and the X(t)’s at the middle time range (round t = K/2) has the biggest
impact. Here, we choose K = 35, 15 to generate the case of 15% and 25% censoring,
respectively.
(II) β(t) = 0.6·g(t/K) where g(x) is the density function of Beta(2,4) distribution, i.e.
g ∼ Beta(2, 4). This is a situation where the X(t)’s at earlier time have bigger impact
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to the survival outcome then the ones at later time. Again we choose K = 35, 15
respectively to generate 15% and 25% censoring.
(III) β(t) = 0.4 · g(t/K) where we choose g(x) = sin{(2x + 1)pi}. This is a situation
where the impact of X(t)’s are negative (reducing the hazard) at earlier time and
positive (increasing the hazard) at later time. Here we choose K = 8, 7 respectively
to generate 15% and 25% censoring.
We only consider administrative censoring at C = K, then the observed survival
outcome can be generated as Yi = Ti ∧ C and ∆i = I(Ti > C). In each scenario, K
is chosen such that about 15% censoring will be generated.
To set up the spline, we need to choose a set of knots. These can be viewed as
parameters that have to be estimated according to a goodness-of-fit criterion, e.g.
the Akaike information criterion (AIC) (McCullagh and Nelder , 1989). Several meth-
ods have been described in the literature and are in general referred to as adaptive
knot selection (Hastie and Tibshirani , 1990; Friedman, 1991). Here we use a simple
approach to choose knots at the corresponding quantiles of the covariate. Three dif-
ferent numbers of interior knots for the B-splines are tried, which are 2, 3 and 4. The
results are quite similar and we present the results for the case with 2 interior knots.
For all scenarios, we simulate 150 datasets each with 500 subjects, and we use boot-
strap with B = 100 for each dataset to estimate the variances. We choose to use cubic
B-splines to approximate the log hazard function. From Table 2.1, which summarizes
the results on the estimation of the treatment effect, we can see that the estimates
for γ from all scenarios are close to the truth (γ0 = −2.0), while the situations with
lower censoring rates tend to have smaller bias. And the coverage rates are close to
95%. As the coverage rates are calculated from bootstrap resampling, it is possible
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that larger B for bootstrap could further improve the coverage rates (to be more close
to 95%). From Figure 2.1 and Figure 2.2, we can also see that the estimated βˆ(t)’s
(solid red lines) are close to the true curves (dash line in blue), and the true curves are
within the 95% confidence intervals calculated from the bootstrap sampling (dotted
lines in green).
Table 2.1: The estimation for the time-independent coefficient γ: the estimation γˆn
under different setting of true β0(t) are listed here (true γ0 = −2.0). For
Scenario I, the true β0(t) has a symmetric shape (∼ Beta(3, 3)) over the
time range considered, in Scenario II β0(t) has the shape of Beta(2, 4),
and in Scenario III, β0(t) has the shape of a sin function (∼ sin(2pit/K)).
The mean estimation is average over the 150 replicates, while the empirical
standard error is the estimate of the variance from the bootstrap procedure
(B = 100), averaged over the 150 replicates. The mean bias is the averaged
bias for the point estimation, and the coverage rate is also calculated from
the bootstrap results in each replicate and average over the 150 rounds.
censoring Shape of β(t) Mean Est. bsSE Mean Bias Coverage %
Scenario I -1.939 0.164 0.061 92.0
15% Scenario II -1.885 0.188 0.115 93.3
Scenario III -1.927 0.182 0.073 96.0
Scenario I -1.926 0.186 0.074 91.0
25% Scenario II -1.867 0.200 0.133 92.5
Scenario III -1.925 0.188 0.075 93.6
Note: bsSE is the mean of the bootstrapped standard errors, Coverage is the
coverage probability of the 95% confidence interval.
2.6 Discussion
In this Chapter, we propose an AFT model to account for possible cumulative
effect of the time-dependent covariates X(t). We assume a rather general form of the
model to allow β(t), the coefficients of X(t), to be time-varying. too. The estimat-
ing procedure is statistically efficient and computationally feasible. In this chapter,
we assume a parametric distribution for the error term in model (2.2). Instead of a
lognormal distribution, there are several other parametric distribution models that
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Figure 2.1: Estimated Time-Varying Coefficient for X(t) for 15% censoring cases.
Three scenarios are plotted here, where the upper left panel is for Scenario
I, where the true β0(t) has a symmetric shape (∼ Beta(3, 3)) over the
time range considered, the upper right panel is for Scenario II, where the
earlier X(t) values have more impacts (∼ Beta(2, 4)), and the lower left
panel is for Scenario III, where X(t) values have a positive effect (increase
hazard) at beginning and negative effect (reduce hazard) at later time
(∼ sin(2pit/K)). In all cases, the dashed line in blue is the truth β0(t).
the solid line in red is the estimation averaged over 150 datasets, and the
dotted lines in green show the averaged the 95% confidence interval which
come from the bootstrap procedure.
21
0 5 10 15
0.
0
0.
5
1.
0
1.
5
Estimated Weight for Scenario I, 25% Censoring
time(yr)
w
e
ig
ht
average wt
95% CI wt
true wt
0 5 10 15
0.
0
0.
5
1.
0
1.
5
Estimated Weight for Scenario II, 25% Censoring
time(yr)
w
e
ig
ht
average wt
95% CI wt
true wt
0 1 2 3 4 5 6 7
−
0.
4
−
0.
2
0.
0
0.
2
0.
4
Estimated Weight for Scenario III, 25% Censoring
time(yr)
w
e
ig
ht
average wt
95% CI wt
true wt
Figure 2.2: Estimated Time-Varying Coefficient for X(t) for 25% censoring cases.
Similar as in Figure 2.1 Scenario I - III are plotted. In all cases, the
dashed line in blue is the truth β0(t). the solid line in red is the esti-
mation averaged over 150 datasets, and the dotted lines in green show
the averaged the 95% confidence interval which come from the bootstrap
procedure.
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are frequently used in survival analysis. For example, under certain circumstances,
a Weibull distribution or log-logistic model are preferred (Kalbfleisch and Prentice,
2011). It is straightforward to extend the proposed estimation procedure to models
with other parametric distribution assumptions. Furthermore, the baseline cumu-
lative hazard function Λ0(t) can also be estimated non-parametrically. However, it
would be challenging both theoretically and numerically to accommodate two non-
parametric terms in the same model.
In model (2.2), we have both time-dependent and fixed effects, in practice, it al-
lows the more complicated association between the survival time and time-dependent
variable. However, one need to be cautious in interpreting γ and β(t). For example,
if X(t) is the PSA measured over time, and Z is some treatment decision made at
baseline, then γ would have the interpretation of a treatment effect, given the same
trajectory of X(t), the treatment will prolong the survival time multiplicatively by a
factor of e−γ. The interpretation for β(t) would be even harder, especially for practi-
tioners who are used to deal with the hazard ratios in Cox proportional hazard model.
AFT model do provide a more attractive alternative in a lot of cases, for example,
in some scenarios, when the outcome is data with censoring, like measurement with
lower detect boundary, the outcomes will be censored on the left as they are under
certain threshold that the equipment can detect, then the hazard function may not
have very good practical meaning, while the interpretation of coefficients in AFT
model may be more preferred.
In the model setting, we assume that β(t) is only indexed by t. Suppose we are
now looking at time τ , it is more realistic to assume that the effect of PSA (X(t),
t ∈ [0, τ ]) on the current hazard λ(τ) not only depends on t, but also depends on
τ , i.e. β(t, τ). An explanation is that the magnitude of the effect of X(t) on λ(τ)
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depends on t, and also how close this t is to the point τ . For example, we would
expect the PSA value at 2 years to have more impact on the hazard at 3 year than
on the hazard at 10 year. This would require splines in two-dimensions and becomes
harder to study its properties.
In this chapter, we consider the case where the indicator for treatment is time-
independent. In many biomedical studies, it is common to that the treatment initia-
tion time for subject i, denoted as Si is also random. So another extension of possible
interest is that we allow the treatment indicator to be a time-dependent covariate,
so we would have two time-dependent covariates, one with time varying coefficient
and one with a time-independent coefficient. For this we would consider the following
model
ei =
Ti∫
0
exp{β(u)Xi(u) + γZi(u)}du
where Zi(u) is a step function that jumps from 0 to 1 at u = Si.
2.7 Appendix: Proof of the Technical Results
2.7.1 The Derivatives
In order to work on the asymptotic properties, first, we derive the form of the
first and second derivatives of the log likelihood function. As mentioned above, the
log likelihood for a single observation is:
l(β, γ, σ) =∆{β(Y )X(Y )} −∆R(Y ; β)−∆ log σ
+ ∆ log φ
(
R(Y ; β) + γZ
σ
)
+ (1−∆) log Φ
(
−R(Y ; β) + γZ
σ
)
For any fixed β(·) ∈ Ω, let {β(η)(·) : η in a neighborhood of 0 ∈ R} be a smooth
curve in Ω running through β(·) at η = 0, i.e., β(η)(·)|η=0 = β(·). and ∂β(η)∂η |η=0 = h.
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Furthermore, we write
R = R(Y, β) = log
Y∫
0
eβ(u)X(u)du
R1 = log
Y∫
0
h(u)X(u)eβ(u)X(u)du
R2 = log
Y∫
0
h1(u)h2(u)X
2(u)eβ(u)X(u)du
and
1− Φ = Φ(−(R + γZ)/σ)
φ = φ((R + γZ)/σ) = φ(−(R + γZ)/σ)
φ(1) = φ(1)((R + γZ)/σ)
φ(2) = φ(2)((R + γZ)/σ)
then we can write out the derivatives as
l˙1(β, γ, σ)[h] = ∆h(Y )X(Y )−∆e
R1
eR
+
∆
σ
φ(1)
φ
eR1
eR
− (1−∆)
σ
φ
(1− Φ)
eR1
eR
l˙2(β, γ, σ) =
∆Z
σ
φ(1)
φ
− (1−∆)Z
σ
φ
(1− Φ)
l˙3(β, γ, σ) = −∆
σ
− ∆(R + γZ)
σ2
φ(1)
φ
− (1−∆)(R + γZ)
σ2
φ
1− Φ
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The second derivatives are:
l¨11(β, γ, σ)[h1, h2] =−∆e
R2
eR
+ ∆
e2R1
e2R
+
∆
σ2
e2R1
e2R
φ(2)
φ
+
∆
σ
eR2
eR
φ(1)
φ
− ∆
σ2
e2R1
e2R
(
φ(1)
φ
)2
− ∆
σ
e2R1
e2R
φ(1)
φ
− (1−∆)
σ2
e2R1
e2R
φ(1)
(1− Φ) −
(1−∆)
σ
eR2
eR
φ
(1− Φ)
− (1−∆)
σ2
e2R1
e2R
(
φ
(1− Φ)
)2
+
(1−∆)
σ
e2R1
e2R
φ
(1− Φ)
l¨22(β, γ, σ) =
∆Z2
σ2
φ(2)
φ
− ∆Z
2
σ2
(
φ(1)
φ
)2
− (1−∆)Z
2
σ2
φ(1)
1− Φ −
(1−∆)Z2
σ2
(
φ
1− Φ
)2
l¨33(β, γ, σ) =
∆
σ2
+
∆(R + γZ)2
σ4
φ(2)
φ
+
2∆(R + γZ)
σ3
φ(1)
φ
− ∆(R + γZ)
2
σ4
(
φ(1)
φ
)2
+
(1−∆)(R + γZ)2
σ4
φ(1)
1− Φ +
2(1−∆)(R + γZ)
σ3
φ
1− Φ
+
(1−∆)(R + γZ)2
σ4
(
φ
1− Φ
)2
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l¨12(β, γ, σ)[h] =
∆Z
σ2
eR1
eR
φ(2)
φ
− ∆Z
σ2
eR1
eR
(
φ(1)
φ
)2
− (1−∆)Z
σ2
eR1
eR
φ(1)
1− Φ
− (1−∆)Z
σ2
eR1
eR
(
φ
1− Φ
)2
l¨13(β, γ, σ)[h] =− ∆(R + γZ)
σ3
eR1
eR
φ(2)
φ
− ∆
σ2
eR1
eR
φ(1)
φ
+
∆(R + γZ)
σ3
eR1
eR
(
φ(1)
φ
)2
+
(1−∆)(R + γZ)
σ3
eR1
eR
φ(1)
1− Φ +
(1−∆)
σ2
eR1
eR
φ
1− Φ
+
(1−∆)(R + γZ)
σ3
eR1
eR
(
φ
1− Φ
)2
l¨23(β, γ, σ) =− ∆Z(R + γZ)
σ3
φ(2)
φ
− ∆Z
σ2
φ(1)
φ
+
∆Z(R + γZ)
σ3
(
φ(1)
φ
)2
+
(1−∆)Z(R + γZ)
σ3
φ(1)
1− Φ +
(1−∆)Z
σ2
φ
1− Φ
+
(1−∆)Z(R + γZ)
σ3
(
φ
1− Φ
)2
2.7.2 Outline of the Proofs
In the section, we provide some details on the theorems. The following conditions
are sufficient to guarantee the forthcoming properties.
(C1) Xi(t) is bounded for t ∈ R+, i.e. ∀t, ∃C s.t. P(||Xi(t)|| ≤ C) = 1
(C2) γ ∈ Γ, σ ∈ Σ, where Γ is a compact subset of R, and Σ is a compact subset
of R+.
(C3) β(·) ≥ 0, ∀t ∈ R+.
(C4) ∀t, ∃C s.t. P(0 ≤ ||β(t)Xi(t)|| ≤ C) = 1
(C5) Let B denote the collection of bounded functions β on (0, a] with bounded
derivatives β(j), j = 1, · · · , k, and the kth derivative β(k) satisfies the following Lips-
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chitz continuity condition:
∣∣β(k)(s)− β(k)(t)∣∣ ≤ L |s− t|m for s, t ∈ (0, a]
We have θ = (β, γ, σ)T , β ∈ B, γ ∈ Γ and σ ∈ Σ, Let Θ = Ω×Γ×Σ be the parameter
space of θ. We define a distance between θ1,θ2 ∈ Θ by
d(θ1,θ2) = {||β2 − β1||2 + |γ2 − γ1|2 + |σ2 − σ2|2}1/2
where | · | is the Euclidean distance and ‖ · ‖ is some norm. Let Θn be the sieve
parameter space, a sequence of increasing subsets of the parameter space growing
dense in Θ as n→∞.
2.7.2.1 Proof of Theorem 2.1
For Theorem 2.1, in order to give the convergence rate for θˆn, we first prove
the asymptotic consistency, i.e. : d(θˆn,θ0) −→ 0. Let M(θ) = Pl(θ;Y,∆,W ) and
Mn(θ) = Pnl(θ;Y,∆,W ). Hence Mn(θ)−M(θ) = (Pn−P )l(θ;Y,∆,W ). According
to Theorem 5.7 in van der Vaart (1998), this would be equivalent to check the following
the conditions:
(A1) Let L1 = {l(θ;Y,∆,W ) : θ ∈ Θn} then the c-bracketing number for L1
with L1(P )-norm is bounded by some C(1/)
na thus L1 is Glivenko-Cantelli and
supθ∈Θn |Mn(θ) −M(θ)| →p 0
(A2) M(θ0)−M(θ) ≥ 0
(A3) For β0 ∈ B, there exists a β0,n ∈ Bn of order m ≥ p + 2 such that ‖β0,n −
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β0‖∞ ≤ Cq−pn = O(n−pν) then let θ0,n = (β0,n, γ0, σ0) then we can have
Mn(θˆn)−M(θ0) = Mn(θˆn)−Mn(θ0,n) +Mn(θ0,n)−M(θ0)
≥ Pn{l(θ0,n;Y,∆,W )− l(θ0;Y,∆,W )}
≥ −op(1)
thus Cd2(θ0,θ0,n)→ 0
(A4) Furthermore we want
Mn(θˆn)−M(θ0) ≥(Pn − P ){l(β0,n, γ0, σ0;Y,∆,W )− l(β0, γ0, σ0;Y,∆,W )}
+ P{l(β0,n, γ0, σ0;Y,∆,W )− l(β0, γ0, σ0;Y,∆,W )}
=−Op(n−2pν)
=−Op
(
n−min(pν,(1−ν)/2)
)
Proof of (A1)
Let L1 = {l(θ;Y,∆,W ) : θ ∈ Θn}. by the calculation of Shen and Wong (1994),
page 597, ∀ > 0, there exists a set of brackets {[βLj , βUj ] : j = 1, 2, · · · , [(1/)C1qn ]}
such that for any β ∈ Bn, one has βLj (u) ≤ β(u) ≤ βUj (u) for some 1 ≤ j ≤ [(1/)C1qn ]
and all u ∈ [0, b], and P |βUj (Y,∆,W )− βUj (Y,∆,W )| ≤ . Since Γ ∈ R is compact,
Γ can be covered by [C2/] balls with radius ; that is, for any γ ∈ Γ, there exists
an 1 ≤ s1 ≤ [C2/] such that |γ − γs1| ≤ . Similarly, for any σ ∈ Σ, there exists an
1 ≤ s2 ≤ [C3/] such that |σ − σs2| ≤ . Then ∀l(β, γ, σ;Y,∆,W ) ∈ L1, ∃s1, s2, j,
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s.t. l ∈ [lLs1,s2,j(Y,∆,W ), lUs1,s2,j(Y,∆,W )], for any sample point (Y,∆,W ), where
lLs1,s2,j(Y,∆,W ) =∆i
{
βLj (Yi)Xi(Yi) + (γs1 − )Zi
}
−∆i log
Yi∫
0
eβ
U
j (u)Xi(u)du− (γs1 + )Zi −∆i log(σ2s2 + )
+ ∆i log φ
(
log
∫ Yi
0
eβ
L
j (u)Xi(u)du+ (γs1 − )Zi
σ2s2 + 
)
+ (1−∆i) log Φ
(
− log
∫ Yi
0
eβ
U
j (u)Xi(u)du+ (γs1 + )Zi
σ2s2 − 
)
lUs1,s2,j(Y,∆,W ) =∆i{βUj (Yi)Xi(Yi) + (γs1 + )Zi}
−∆i log
Yi∫
0
eω
L
j (u)Xi(u)du− (γs1 − )Zi −∆i log(σ2s2 − )
+ ∆i log φ
(
log
∫ Yi
0
eβ
U
j (u)Xi(u)du+ (γs1 + )Zi
σ2s2 − 
)
+ (1−∆i) log Φ
(
− log
∫ Yi
0
eβ
L
j (u)Xi(u)du+ (γs1 − )Zi
σ2s2 + 
)
By Taylor expansion and some calculation, we have for all s1, s2, s3 and i
P (|(lUs1,s2,s3,i − lLs1,s2,s3,i)(Y,∆,W )|) ≤ C ′1
thus the c-bracketing number for L1 = {l(θ;Y,∆,W ) : θ ∈ Θn} with L1(P )-norm is
bounded by C(1/)C1qn+3, so L1 is Glivenko-Cantelli, supθ∈Θn |Mn(θ)−M(θ)| →p 0
Proof of (A2)
Since Pl(β, γ, σ) is maximized at (β0, γ0, σ0), so its derivatives at (β0, γ0, σ0) are equal
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to 0. so by Taylor expansion,
M(θ0)−M(θ) =Pl(θ0;Y,∆,W )− Pl(θ;Y,∆,W )
=
1
2
P
{
l¨11(θ0)[β − β0, β − β0] + l¨22(θ0)(γ − γ0)2 + l¨33(θ0)(σ − σ0)2
+2l¨12(θ0)(γ − γ0)[β − β0] + 2l¨13(θ0)(σ − σ0)[β − β0]
+2l¨23(θ0)(γ − γ0)(σ − σ0)
}
+ o
(
d2(θ,θ0)
)
=A+ o
(
d2(θ,θ0)
)
Before we proceed to find the upper bound for A, first, by Cauchy-Schwarz Inequality,
we have
Y∫
0
[{β(u)− β0(u)}X(u)]2 · exp {β0(u)X(u)} du
≤
Y∫
0
[{β(u)− β0(u)}X(u)]2 du ·
Y∫
0
exp {β0(u)X(u)} du
.eR
Y∫
0
[{β(u)− β0(u)}X(u)]2 du
.eR‖β − β0‖2Y
where . denotes that the left-hand side is bounded above by a constant times the
right-hand side, similarly,
Y∫
0
{β(u)− β0(u)}X(u) · exp {β0(u)X(u)} du
≤
Y∫
0
{β(u)− β0(u)}X(u)du ·
Y∫
0
exp {β0(u)X(u)} du
.eR‖β − β0‖Y
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then we have 0 ≤ eR2 . eR · ‖β − β0‖2Y and 0 ≤ (eR1)2 . (eR)2 · ‖β − β0‖2Y thus
l¨11(β0, γ0, σ0)[β − β0, β − β0] =−∆e
R2
eR
+ ∆
e2R1
e2R
+
∆
σ20
e2R1
e2R
φ(2)
φ
+
∆
σ0
eR2
eR
φ(1)
φ
− ∆
σ20
e2R1
e2R
(
φ(1)
φ
)2
− ∆
σ0
e2R1
e2R
φ(1)
φ
− (1−∆)
σ20
e2R1
e2R
φ(1)
(1− Φ)
− (1−∆)
σ0
eR2
eR
φ
(1− Φ) −
(1−∆)
σ20
e2R1
e2R
(
φ
1− Φ
)2
+
(1−∆)
σ0
e2R1
e2R
φ
(1− Φ)
.
{
∆
σ20
·
∣∣φ(2)∣∣
φ
+
∆
σ0
· 2
∣∣φ(1)∣∣
φ
+
(1−∆)
σ20
∣∣φ(1)∣∣
1− Φ
+
(1−∆)
σ0
|φ|
1− Φ
}
· ‖β − β0‖2Y
similarly, we can have
l¨12(β0, γ0, σ
2
0)[β − β0] = l¨21(β0, γ0, σ20)[β − β0]
=
∆Z
σ20
eR1
eR
φ(2)
φ
− ∆Z
σ20
eR1
eR
(
φ(1)
φ
)2
− (1−∆)Z
σ20
eR1
eR
φ(1)
1− Φ −
(1−∆)Z
σ20
eR1
eR
(
φ
1− Φ
)2
.
{
∆
σ30
∣∣φ(2)∣∣
φ
+
∆
σ20
(φ(1))2
φ2
+
(1−∆)
σ20
∣∣φ(1)∣∣
1− Φ
}
|Z| · ‖β − β0‖Y
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l¨13(β0, γ0, σ
2
0)[β − β0] = l¨31(β0, γ0, σ20)[β − β0]
=− ∆(R + γ0Z)
σ30
eR1
eR
φ(2)
φ
− ∆
σ20
eR1
eR
φ(1)
φ
+
∆(R + γ0Z)
σ30
eR1
eR
(
φ(1)
φ
)2
+
(1−∆)(R + γ0Z)
σ30
eR1
eR
φ(1)
1− Φ +
(1−∆)
σ20
eR1
eR
φ
1− Φ +
(1−∆)(R + γ0Z)
σ30
eR1
eR
(
φ
1− Φ
)2
.
{
∆
σ30
∣∣φ(2)∣∣
φ
|R|+ ∆
σ30
∣∣φ(2)∣∣
φ
|γ0| |Z|+ ∆
σ20
∣∣φ(1)∣∣
φ
+
∆
σ30
(φ(1))2
φ2
|R|+ ∆
σ30
(φ(1))2
φ2
|γ0| |Z|
+
(1−∆) ∣∣φ(1)∣∣
σ30(1− Φ)
|R|+ (1−∆)
∣∣φ(1)∣∣
σ30(1− Φ)
|γ0| |Z|+ (1−∆)
σ20
φ
1− Φ +
(1−∆)
σ30
φ2
(1− Φ)2 |R|
+
(1−∆)
σ30
φ2
(1− Φ)2 |γ0| |Z|
}
· ‖β − β0‖Y
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Thus, we can calculate the following quantity
D1 =l¨11(θ0)[β − β0, β − β0] + l¨22(θ0)(γ − γ0)2 + l¨33(θ0)(σ − σ0)2
+ 2l¨12(θ0)[β − β0](γ − γ0) + 2l¨13(θ0)[β − β0](σ − σ0) + 2l¨23(θ0)(γ − γ0)(σ − σ0)
.
{
∆
σ20
·
∣∣φ(2)∣∣
φ
+
∆
σ0
· 2
∣∣φ(1)∣∣
φ
+ ∆ +
(1−∆)
σ20
∣∣φ(1)∣∣
1− Φ +
(1−∆)
σ0
|φ|
1− Φ
}
· ‖β − β0‖2Y +
{
∆Z2
σ20
φ(2)
φ
− ∆Z
2
σ20
(
φ(1)
φ
)2
− (1−∆)Z
2
σ20
φ(1)
1− Φ
−(1−∆)Z
2
σ20
(
φ
1− Φ
)2}
· (γ − γ0)2 +
{
∆
σ20
+
∆(R + γ0Z)
2
σ40
φ(2)
φ
+
2∆(R + γ0Z)
σ30
φ(1)
φ
− ∆(R + γ0Z)
2
σ40
(
φ(1)
φ
)2
+
(1−∆)(R + γ0Z)2
σ40
φ(1)
1− Φ +
2(1−∆)(R + γ0Z)
σ30
φ
1− Φ
+
(1−∆)(R + γ0Z)2
σ40
(
φ
1− Φ
)2}
· (σ − σ0)2 + 2
{
∆
σ30
∣∣φ(2)∣∣
φ
+
∆
σ20
(φ(1))2
φ2
+
(1−∆)
σ20
∣∣φ(1)∣∣
1− Φ
}
· ‖β − β0‖Y (γ − γ0) + 2
{
∆
σ30
∣∣φ(2)∣∣
φ
|R|+ ∆
σ30
∣∣φ(2)∣∣
φ
|γ0| |Z|
+
∆
σ20
∣∣φ(1)∣∣
φ
+
∆
σ30
(φ(1))2
φ2
|R|+ ∆
σ30
(φ(1))2
φ2
|γ0| |Z|+
(1−∆) ∣∣φ(1)∣∣
σ30(1− Φ)
|R|+ (1−∆)
∣∣φ(1)∣∣
σ30(1− Φ)
|γ0| |Z|
+
(1−∆)
σ20
φ
1− Φ +
(1−∆)
σ30
φ2
(1− Φ)2 |R|+
(1−∆)
σ30
φ2
(1− Φ)2 |γ0| |Z|
}
· ‖β − β0‖Y (σ − σ0)
+ 2
{
−∆Z(R + γ0Z)
σ30
φ(2)
φ
− ∆Z
σ20
φ(1)
φ
+
∆Z(R + γ0Z)
σ30
(
φ(1)
φ
)2
+
(1−∆)Z(R + γ0Z)
σ30
φ(1)
1− Φ +
(1−∆)Z
σ20
φ
1− Φ +
(1−∆)Z(R + γ0Z)
σ30
(
φ
1− Φ
)2}
· (γ − γ0)(σ − σ0)
=∆N1 + (1−∆)N2
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where we denote
N1 =
{
1
σ20
·
∣∣φ(2)∣∣
φ
+
1
σ0
· 2
∣∣φ(1)∣∣
φ
+ 1
}
· ‖β − β0‖2Y +
{
Z2
σ20
φ(2)
φ
− Z
2
σ20
(
φ(1)
φ
)2}
· (γ − γ0)2
+
{
1
σ20
+
(R + γ0Z)
2
σ40
φ(2)
φ
+
2(R + γ0Z)
σ30
φ(1)
φ
− (R + γ0Z)
2
σ40
(
φ(1)
φ
)2}
· (σ − σ0)2
+ 2
{
1
σ30
∣∣φ(2)∣∣
φ
+
1
σ20
(φ(1))2
φ2
}
· ‖β − β0‖Y (γ − γ0) + 2
{
1
σ30
∣∣φ(2)∣∣
φ
|R|+ 1
σ30
∣∣φ(2)∣∣
φ
|γ0| |Z|
+
1
σ20
∣∣φ(1)∣∣
φ
+
1
σ30
(φ(1))2
φ2
|R|+ 1
σ30
(φ(1))2
φ2
|γ0| |Z|
}
· ‖β − β0‖Y (σ − σ0)
+ 2
{
−Z(R + γ0Z)
σ30
φ(2)
φ
− Z
σ20
φ(1)
φ
+
Z(R + γ0Z)
σ30
(
φ(1)
φ
)2}
(γ − γ0)(σ − σ0)
After some calculation and by CauchySchwarz inequality, we have
N1 .C1 ‖β − β0‖2Y + C2(γ − γ0)2 + C3(σ − σ0)2
. ‖β − β0‖2Y + (γ − γ0)2 + (σ − σ0)2
where C1, C2 and C3 are constant with respect to θ = (β(·), γ, σ). Similarly, we can
have
N2 =
{
1
σ20
∣∣φ(1)∣∣
1− Φ +
1
σ0
|φ|
1− Φ
}
· ‖β − β0‖2Y +
{
−Z
2
σ20
φ(1)
1− Φ −
Z2
σ20
(
φ
1− Φ
)2}
· (γ − γ0)2
+
{
(R + γ0Z)
2
σ40
φ(1)
1− Φ +
2(R + γ0Z)
σ30
φ
1− Φ +
(R + γ0Z)
2
σ40
(
φ
1− Φ
)2}
· (σ − σ0)2
+ 2
1
σ20
∣∣φ(1)∣∣
1− Φ · ‖β − β0‖Y (γ − γ0) + 2
{ ∣∣φ(1)∣∣
σ30(1− Φ)
|R|+
∣∣φ(1)∣∣
σ30(1− Φ)
|γ0| |Z|
+
1
σ20
φ
1− Φ +
1
σ30
φ2
(1− Φ)2 |R|+
1
σ30
φ2
(1− Φ)2 |γ0| |Z|
}
· ‖β − β0‖Y (σ − σ0)
+ 2
{
Z(R + γ0Z)
σ30
φ(1)
1− Φ +
Z
σ20
φ
1− Φ +
Z(R + γ0Z)
σ30
(
φ
1− Φ
)2}
· (γ − γ0)(σ − σ0)
. ‖β − β0‖2Y + (γ − γ0)2 + (σ − σ0)2
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Thus
D1 .∆N1 + (1−∆)N2
. ‖β − β0‖2Y + (γ − γ0)2 + (σ − σ0)2
=d2(θ,θ0),
we can then have A = 1
2
P{D1} ≤ Cd2(θ,θ0) with some C for which is bounded.
Proof of (A3)
Mn(θˆn)−Mn(θ0) = Mn(θˆn)−Mn(θ0.n) +Mn(θ0,n)−Mn(θ0)
≥ Pnl(θ0,n;Y,∆,W )− Pnl(θ0;Y,∆,W )
= (Pn − P ) {l(θ0,n;Y,∆,W )− l(θ0;Y,∆,W )}+M(θ0,n)−M(θ0)
Define L2 = {l(β, γ0, σ0)− l(β0, γ0, σ0) : β ∈ Bn, and ‖β − β0‖ ≤ Cn−pν} with the
-bracketing number associated L2(P )-norm bounded by (1/)
Cqn . Thus L2 is P-
Donsker. So
P {l(β, γ0, σ0;Y,∆,W )− l(β0, γ0, σ0;Y,∆,W )}2 → 0 as n→∞
Hence (Pn − P ) {l(θ0,n;Y,∆,W )− l(θ0;Y,∆,W )} = op
(
n−1/2
)
, by the relationship
between P-Donsker and asymptotic equicontinuity (van der Vaart and Wellner (1996)
Corollary 2.3.12). By the Dominated Convergence Theorem, M(θ0,n) − M(θ0) >
−o(1) as n→∞. Therefore,
Mn(θˆn)−M(θ0) ≥ op(n−1/2)− o(1) = −op(1)
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Combine (A1) - (A3), we have the consistency result, i.e. d(θˆn − θ0) → 0 in proba-
bility. And Condition (A4) further gives the convergence rate.
Proof of (A4)
Here, we need to verify the conditions of Theorem 3.2.5 of van der Vaart and Wellner
(1996) in order to derive the convergence rate. We have
Mn(θˆn)−Mn(θ0) ≤ I1,n + I2,n
where I1,n = (Pn − P ){l(β0,n, γ0, σ0;Y,∆,W ) − l(β0, γ0, σ0;Y,∆,W )} and I2,n =
P{l(β0,n, γ0, σ0;Y,∆,W )− l(β0, γ0, σ0;Y,∆,W )}. By Taylor expansion, we have
I1,n = (Pn − P )
{
l˙2(β˜, γ0, σ0;Y,∆,W )(β0,n − β0)
}
= n−pν+(Pn − P )
{
l˙2(β˜, γ0, σ0;Y,∆,W )
β0,n − β0
n−pν+
}
for any 0 <  < 1/2− pν. Because ‖β0,n− β0‖∞ = O(n−pν) and l˙2(β˜, γ0, σ0;Y,∆,W )
is uniformly bounded due to Conditions (C1) - (C5), we can easily obtain that
P
{
l˙2(β˜, γ0, σ0;Y,∆,W )
β0,n − β0
n−pν+
}2
→ 0
Due to L2 being P-Donsker, using Corollary 2.3.12 of van der Vaart and Well-
ner (1996) again, we can conclude that (Pn − P )
{
l˙2(β˜, γ0, σ0;Y,∆,W )
β0,n−β0
n−pν+
}
=
op(n
−1/2). Hence I1,n = op(n−pν+−1/2) = op(n−2pν).
Similarly, by Taylor expansion, we can argue that M(θ0)−M(θ0,n) ≤ C‖β0,n−β0‖2 =
O(n−2pν), which implies that I2,n = M(θ0,n)−M(θ0) ≥ −O(n−2pν). Thus we conclude
that
Mn(θˆn)−Mn(θ0) ≥ −Op(n−2pν) = Op(n−2 min(pν,(1−ν)/2))
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Let L3(η) = {l(θ) − l(θ0) : β ∈ Bn and d(θ,θ0) ≤ η}. Using the same argument
as that in the proof of consistency, we obtain that the logarithm of the -bracketing
number of L3(η), logN[]{,L3(η), L2(P )} is bounded by Cqn log(η/). This leads to
J[]{,L3(η), L2(P )} =
η∫
0
√
1 + logN[]{,L3(η), L2(P )}d ≤ Cq1/2n η
Because Condition (C1) and (C3) guarantee the uniform boundedness of l(θ), using
Theorem 3.4.1 of van der Vaart and Wellner (1996), the key function βn(η) in The-
orem 3.2.5 of van der Vaart and Wellner (1996) is given by βn(η) = q
1/2
n η + qn/n
1/2.
Note that
n2pνβn(1/n
pν) = npνnν/2 + n2pνnν + n2pνnν/n1/2 = n1/2
{
npν−(1−ν)/2 + n2pν−(1−ν)
}
Therefore, if pν ≤ (1−ν)/2, n2pνβn(1/npν) ≤ n1/2. This implies that if we choose rn =
nmin(pν,(1−ν)/2), it follows that r2nβn(1/rn) ≤ n1/2 and Mn(θˆn)−Mn(θ0) ≥ −Op(r−2n ).
Hence d(θˆn,θ0) = Op(r
−1
n ) = Op
[
n−min{pν,(1−ν)/2}
]
.
2.7.2.2 Proof of Theorem 2.2
For Theorem 2.2, given the efficient score for γ in the censored linear model derived
as follows:
l˙∗γ(θ) =
[
Z − EY˜ ,∆˜,W˜ {Z˜X˜(Y˜ )|R˜ = log
∫ t
0
eβ0(u)X(u)du, ∆˜ = 1}
EY˜ ,∆˜,W˜ {X˜2(Y˜ )|R˜ = log
∫ t
0
eβ0(u)X(u)du, ∆˜ = 1}
]
× 1
σ
{
∆
φ′({R(Y ; β0) + γZ} /σ)
φ({R(Y ; β0) + γZ} /σ) − (1−∆)
φ(−{R(Y ; β0) + γZ} /σ)
Φ(−{R(Y ; β0) + γZ} /σ)
}
where R(s; β0) = log
∫ s
0
exp{β0(u)X(u)}du. Suppose that the conditions in Theorem
1 hold and I(θ0) = EY,∆,W
{
l˙∗γ(θ0)
⊗2
}
is nonsingular, then in order to derive the
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asymptotic normality for γˆ, we need to verify the conditions of the general theorem
given in Appendix B of Zhang et al. (2009) (simplified version of the general theorem
given in Huang et al. (1996)).
(B1) Pnl˙γ(θˆn;Y,∆,W ) = op
(
n−1/2
)
and Pnl˙β(θˆn;Y,∆,W )(ξ0) = op
(
n−1/2
)
(B2) (Pn − P )
{
l∗γ(θˆn;Y,∆,W )− l∗γ(θ0;Y,∆,W )
}
= op(n
−1/2)
(B3) P
{
l∗γ(θˆn;Y,∆,W )− l∗γ(θ0;Y,∆,W )
}
= −I(θ0)(γˆn − γ0) + op(|γˆn − γ0|) +
op
(
n−1/2
)
For Condition (B1), we only need to verify that Pnl˙β(θˆn)(ξ0) = op
(
n−1/2
)
, since
Pnl˙γ(θˆn) ≡ 0. Because ξ0 has a bounded derivative, it is also a function with bounded
variation. Then it can be easily shown using the argument in Billingsley (1986), that
there exist a ξ0,n ∈ Sn(Dn, Kn,m) such that ‖ξ0,n − ξ0‖ = O(q−1n ) = O(n−ν) and
Pnl˙β(θˆn)(ξ0,n) = 0. Therefore we can write Pnl˙β(θˆn)(ξ0) = I3,n + I4,n, where
I3,n = (Pn − P ) l˙β(θˆn)(ξ0 − ξ0,n)
I4,n = P
{
l˙β(θˆn)(ξ0 − ξ0,n)− l˙β(θ0)(ξ0 − ξ0,n)
}
Let L4 =
{
l˙β(θ)(ξ0 − ξ) : θ ∈ Θn, ξ ∈ Sn(Dn, Kn,m) and ‖ξ0 − ξ‖ ≤ n−ν
}
. It can
be similarly argued that the -bracketing number associated with L2(P )-norm is
bounded by C3(1/)
d+C4qn which leads L4 being a P-Donsker due to Theorem 19.5
of van der Vaart (1998). Furthermore, for any r(θ, ξ;x) ∈ L4, Pr2 → 0 as n → ∞.
Hence I3,n = op(n
−1/2) by Corollary 2.3.12 of van der Vaart and Wellner (1996). By
Cauchy-Schwatz inequality and regularity conditions, it can be easily shown that
I4,n ≤ Cd(θˆ,θ0)‖ξ0 − ξ0,n‖ =Op
(
n−min(nu,(1−ν)/2)n−ν
)
=Op
(
n−min(ν(p+1),(1+ν)/2)
)
=op(n
−1/2)
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So (B1) holds.
Condition (B2) holds by similarly verifying that the class L5(η) =
{
l∗β(θ)− l∗β(θ0) :
θ ∈ Θn and d(θ,θ0) ≤ η} is P-Donsker and for any r(θ) ∈ L5(η), Pr2 → 0 as η → 0.
Condition (B3) can be easily established using Taylor expansion and the conver-
gence rate derived in Theorem 2.1.
2.7.3 The Efficient Score Functions
In this section, we study the semiparametric efficiency bound of the proposed
estimator for finite dimensional parameter γ. The semiparametric efficient score for
γ of a single observation can be written as
l˙∗γ(θ0) = l˙γ(θ0)− l˙β(θ0)(h∗)
where
h∗(t) =
EY˜ ,∆˜,W˜
[
Z˜X˜(Y˜ )|R˜0 = log
∫ t
0
eβ0(u)X(u)du, ∆˜ = 1
]
EY˜ ,∆˜,W˜
[
X˜(Y˜ )X˜(Y˜ )|R˜0 = log
∫ t
0
eβ0(u)X(u)du, ∆˜ = 1
]
To see this more clearly, we only need to proof that for the submodel β(t) + ηh∗(t)
with the direction h∗ ∈ H, the following equation will be held ∀h ∈ H:
EY,∆,W
[{
l˙γ(θ0)− l˙β(θ0)(h∗)
}
l˙β(θ0)(h)
]
= 0 (2.6)
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From the form of score functions, we have
l˙γ(θ0)− l˙β(θ0)(h∗)
=
∆Z
σ0
φ
(1)
0
φ0
− (1−∆)Z
σ0
φ0
(1− Φ0) + ∆Z −∆
∫ Y
0
Zeβ0(u)X(u)du∫ Y
0
eβ0(u)X(u)du
−∆h∗(Y )X(Y ) + ∆
∫ Y
0
h∗(u)X(u)eβ0(u)X(u)du∫ Y
0
eβ0(u)X(u)du
− ∆
σ0
φ
(1)
0
φ0
∫ Y
0
h∗(u)X(u)eβ0(u)X(u)du∫ Y
0
eβ0(u)X(u)du
+
(1−∆)
σ0
φ0
(1− Φ0)
∫ Y
0
h∗(u)X(u)eβ0(u)X(u)du∫ Y
0
eβ0(u)X(u)du
=∆{Z − h∗(Y )X(Y )}
+
∫ Y
0
{Z − h∗(u)X(u)}eβ0(u)X(u)du∫ Y
0
eβ0(u)X(u)du
×
{
−∆ + ∆
σ0
φ
(1)
0
φ0
− (1−∆)
σ0
φ0
(1− Φ0)
}
where Φ0 = Φ
(
R0+γ0Z
σ0
)
, φ0 = φ
(
R0+γ0Z
σ0
)
and φ
(1)
0 = φ
(1)
(
R0+γ0Z
σ0
)
, with R0 =
log
∫ Y
0
eβ0(u)X(u)du. Notice that
EY,∆,W {Z − h∗(t)X(t)}
=E
E
Z − h∗(t)X(t)|R0 = log
t∫
0
eβ0(u)X(u)du,∆ = 1


=E
E
Z − EY˜ ,∆˜,W˜
[
Z˜X˜(t)|R˜0 = log
∫ t
0
eβ0(u)X(u)du, ∆˜ = 1
]
EY˜ ,∆˜,W˜
[
X˜(t)X˜(t)|R˜0 = log
∫ t
0
eβ0(u)X(u)du, ∆˜ = 1
]X(t)
|R0 = log
t∫
0
eβ0(u)X(u)du,∆ = 1


=0
Equation (2.6) then follows.
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CHAPTER III
Estimation of the Optimal Dynamic Treatment
Regime from Observational Data Using Flexible
Weighting Models
For many chronic diseases, a patient usually has to undergo multiple stages of
treatment. Therefore, the goal of identifying the optimal dynamic treatment regime
is very appealing as it allows a patient to receive the most appropriate treatment
and dose assignment based on his/her evolving history of disease status, treatment,
and other time-dependent clinical covariates. The challenge is to find the best regime
amongst a set of defined regimes from observational data, in which the actual regime
being followed by each subject is not well characterized. Inverse probability weighting
(IPW) based estimators are used in the estimation of causal parameters as an efficient
way to utilize information from an observational study. In this chapter, we focus on
the case where 1) the outcome is time-to-event, and 2) some of the covariates are
time-varying, and possibly follow a complicated pattern. We consider a class of
dynamic treatment regimes that are fully determined by the longitudinal covariates.
A novel Random Forest based IPW scheme is proposed to adjust for the complexity
in the mechanism of adherence to the regime of interest. The optimal regime is then
identified as the one with the largest restricted mean survival time. The performance
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of the proposed method is assessed through simulation studies, which are designed to
mimic the study of salvage treatment in the management of recurrent prostate cancer.
The proposed method can efficiently accommodate complex and possibly unknown
treatment/adherence mechanisms, and it is robust to cases where the proportional
hazard assumption is violated. We apply the method to a longitudinal prostate cancer
study.
3.1 Introduction
Prostate cancer is the most commonly diagnosed cancer among American men.
After initial treatment, patients with clinically localized prostate cancer are actively
monitored for possible cancer recurrence. Levels of prostate-specific antigen (PSA)
are repeatedly measured, and a dramatic rise of this prognostic marker is considered
as an indicator for increased risk of clinical cancer recurrence (Zagars and von Es-
chenbach, 1993). Salvage androgen deprivation therapy (SADT) would be applied as
an effective way to reduce the recurrence rate in these situations. Clinically, ”when to
start SADT” is usually determined by the physician’s own experience and personal
judgment. However, the current biological understanding of the effect of SADT is not
sufficient to determine the optimal time to start because early initiation of SADT has
both risks and benefits. If SADT is given too early when PSA values are still low, it
is wasted during the time when the patient is at low risk while later on the beneficial
effect wears off as the patient develops resistance. On the other hand if the patient
waits to start SADT until PSA is very high, it becomes less effective because the can-
cer is already well established and may have already spread to other sites by that time.
In this chapter, we try to address the above question and make recommendations
on when would be the optimal time to start SADT in terms of prolonging patient’s
cancer recurrence free survival using flexible weighting models based on the longi-
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tudinally collected observational data. This can be framed as a dynamic treatment
regime (DTR) (Murphy , 2003; Robins , 2004), in which dose or treatment is continu-
ously modified according to a patient’s current history and disease status. Identifying
such optimal dynamic decision rules offers an effective vehicle for personalized man-
agement of chronic diseases, for which a patient typically has to be treated at multiple
stages. DTRs help physicians to adapt the type, dosage, and timing of the treatment
at each stage to the evolving disease status, treatment and clinical history, and thus
provide better care by tailoring the treatment individually based on clinical evidence
(Wagner et al., 2001).
In recent years, a large literature has been developed on both designs and analytic
tools for DTRs. Although data from sequential multiple assignment randomized trials
(SMARTs) are desirable (Murphy , 2005), observational studies are the most common
source of data for complex disease studies, and a great deal of effort in statistical
research has concentrated on how to make best use of observational data to construct
DTRs (Wang et al., 2012). Careful thoughts and assumptions are required to make
valid causal inference, especially on how the observational data may restrict the set
of DTRs that can be assessed, which are called the feasible (Robins , 1994) or vi-
able (Wang et al., 2012) DTRs. Murphy (2003) and Robins (2004) generalized the
G-estimation method of structural nested models (Robins , 1986, 1989b, 1997, 2002)
for optimal treatment regime estimation and this approach is efficient when all mod-
els are correctly specified. Q- and A-learning (Watkins and Dayan, 1992; Robins ,
2004; Murphy , 2005) provides a powerful solution especially when the decision rules
depend on multiple covariates. However, the computational burden would increase
as the number of decision-making stages increases. For survival outcomes, treatment
decisions are essentially made on a continuous time base. In these situations, methods
based on inverse probability weighting (IPW) are easier to conduct and provide cer-
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tain robustness against model mis-specifications (Herna´n et al., 2006; Robins et al.,
2008; Orellana et al., 2010a,b). But the validity of these approaches still rely on
expert knowledge to comprehensively understand the treatment assignment mech-
anism. This is challenging in our prostate cancer example, because the treatment
assignment in this observational study is not completely understood, and the typical
proportional hazard assumption is likely to be violated as well when comparing dif-
ferent regimes. Therefore, we propose a method which incorporates flexible modeling
to account for the unknown and potentially complicated treatment assignment mech-
anism. Our method does not require model assumptions for the recurrence hazard
either and can estimate the optimal DTR even when the hazards are not proportional.
Specifically, our proposed method starts with a class of pre-specified viable dynamic
treatment regimes, and evaluates them based on observational data with a time to
event outcome, while imposing minimal assumptions on the structure of the models.
We proceed by artificially censoring subjects when they become noncompliant with a
defined regime under investigation. This censoring potentially induces a bias which
we correct by using a modified version of Inverse Probability of Censoring Weighting
(IPCW) (Robins , 1993). We focus on the survival distribution as the target quantity
of interest and use a weighted version of Nelson Aalen estimator with a flexible data
driven weighting scheme to (1) accurately estimate the survival distribution under
a pre-defined dynamic treatment regime of interest; and (2) compare the survival
distribution under different viable dynamic treatment regimes.
The rest of this chapter is organized as follows. In Section 3.2, we introduce the
notation under the framework of causal inference, and define the dynamic treatment
regimes of interest. In Section 3.3, we establish our method of the weighted Nelson
Aalen estimator and show asymptotic properties of the estimator. In Section 3.4,
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we demonstrate the validity of the proposed method through a simulation study, fol-
lowed by an application illustration in Section 3.5 by applying the proposed method
to a prostate cancer recurrence dataset with the goal of comparing several clinically
meaningful SADT regimens. Finally, we conclude with a discussion in Section 3.6,
some technical details are summarized in Section 3.7.
3.2 Notation and Dynamic Treatment Regimes
Suppose that there are N patients in a clinical trial or an observational study,
each of whom was observed at baseline t0 = 0, and longitudinally at regular inter-
vals t1, t2, · · · , tk, · · · until the end of K time intervals tK (study end) or until the
event of interest (e.g. cancer recurrence or death in our motivating example) occurs,
whichever is earlier. To simplify the problem, we assume that there is no censoring
(e.g. possible loss to follow-up) other than the administrative censoring at time tK .
Before having the event or dropping out, patients will come to the clinic once during
each of the K intervals and have their time dependent covariates (e.g., the PSA level)
measured. Treatment decisions, i.e. whether to start SADT, were made soon after
each clinic visit and at no other time. Assume that the subjects in the cohort are
a random sample from a large population of interest. For patient i at time tk, with
i = 1, · · · , N and k = 0, · · · , K, let Lik denote the time dependent covariates ob-
served at the kth clinic visit. When k = 0, we follow the convention in the literature
and use Li0 to denote all the baseline covariates. Let Rik denote a binary indicator
for event occurrence. Rik takes the value 1 if the patient has experienced the event
of interest by time tk and 0 otherwise. Let Aik denote the kth-specific treatment
prescription which we assume takes values in a finite set Ak = {0, 1}. Since our main
interest is when would be the optimal timing to start the treatment, we assume that
the patient will stay on the treatment once it is initiated. That is, the treatment can
only go from 0 to 1, but not 1 to 0.
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For a given subject i at time tk, k < K (if no event observed before the kth
visit), the observational data would be Aik and Oik = (Lik, Rik). For simplic-
ity, we will suppress the subject index i in the future when no confusion exists,
and use overbars to denote the history of the variable up to the indexed time.
Furthermore, we use capital letters to refer to random variables or vectors, while
lower-case letters are used to denote the observed values of the corresponding ran-
dom variables. For example, the observational data up to time tk is denoted as
(Ak−1,Ok) = (L0, A0,L1, R1, A1,L2, R2, · · · , Ak−1,Lk, Rk) and a possible observed
treatment history up to time tk is denoted as ak = (a0, · · · , ak) ∈ A0×· · ·×Ak = Ak.
Here we consider a causal framework with treatment regime specific counterfactual
outcomes (Robins , 1986). For each patient, L0 is measured before the first treatment
decision, so it is always observed. Let LCk (ak−1) denote the counterfactual covariate
information that would be observed at time tk were the patient to receive treatment
history ak−1 regardless what treatment sequence he actually followed up to tk, and
similarly let RCk (ak−1) denote the corresponding counterfactual event status at time
tk under treatment history ak−1. Then the counterfactual observations are denoted
as
W C =
{
L0,L
C
1 (a0), R
C
1 (a0), · · · ,LCK(aK−1), RCK(aK−1), for allaK−1 ∈ AK−1
}
Notice W C includes all the counterfactual observation up to time tK . However, in
practice, the counterfactual observation would only be meaningful up to the time of
the counterfactual event, if the counterfactual event is before tK . In fact, the pieces
after that time will never be used in the methods that we describe here and we only
include them in W C for ease of notation.
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A dynamic treatment regime g = {gk : k = 0, · · · , K − 1} is a sequential rule for
determining the next treatment prescription Ak at each time tk. The rule gk(ok) ∈ Ak
for k = 0, . . . , K − 1 may depend on part or all of the recorded health information
about the patient’s health up to and including time tk. The optimal regime would be
a regime that maximizes the expected utility function if all patients in the population
follow this rule. Note the expected utility can depend on ok as well as the regime g,
thus it provides a personalized treatment decision. For time to event outcomes, it may
be unrealistic to expect the proportional hazard assumption to hold across different
regimes, thus here we propose to use the restricted mean survival time as the utility
function. If we denote the survival time by T , then for some arbitrary time bound
Tmax, the restricted survival time is defined as min (T, Tmax), and the restricted mean
lifetime can be represented as E {min (T, Tmax)} . It can be shown that the restricted
mean survival time can be represented as the area under the survival curve up to
Tmax, µ =
∫ Tmax
0
S(t)dt. Here Tmax can be chosen as the administrative censoring
time, or longest follow-up time, in our case, tK . For our specific example, Lk = PSAk
for k = 1, 2, · · · , K, while L0 = (PSA0, V0) where V0 is the baseline covariate (e.g. T-
stage of the patient at time t0). In reality, following the initial treatment of prostate
cancer with radiation therapy, PSA will typically decrease, then either remain stable
or follow an increasing trend. A simple treatment regime could be that the patient
starts SADT the first time his PSA level is above a threshold b, after the decreasing
phase has past (practically, we require that the current PSA value to be larger than
the value at the previous visit). To formalize it, we only consider the class of regimes
G ≡ {gb : b ∈ R} = {(gb0, · · · , gbK−1) : b ∈ R} where the treatment indicator at time
tk is
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gbk(O
C
k ) =

0 ifACk−1 = 0 ,PSA
C
k ≤ PSACk−1 , or PSACk ≤ b.
1 ifACk−1 = 0 ,PSA
C
k > PSA
C
k−1 , and PSA
C
k > b.
1 ifACk−1 = 1
(3.1)
In this setting, a treatment regimen gb is fully defined by cut-off value b. The
counterfactual data used in the definition of gbk in (3.1) is specific to the case where
all patients follow gb. If we denote the restricted mean lifetime under this regime gb
to be µb, the optimal regime is gopt = arg max{gb∈G} µb.
Definition (3.1) is based on the assumption that we observe the counterfactual data
under all regimes gb ∈ G. In practice, not all of them can be observed for each
patient, because each patient is observed to experience one and only one treatment
history. So instead of calculating µb from O
C
K(g
b) as if everyone follows gb, we need
to estimate it from the observed data OK . To make this possible, we follow Orellana
et al. (2010a) and make the following standard assumptions. (i) The consistency
assumption states that Ok = O
C
k (Ak−1) =
∑
ak−1∈Ak−1O
C
k (ak−1)I(Ak−1 = ak−1) for
k = 1, · · · , K; that is, a patient’s observed covariates and outcomes are the same as
the potential ones he would exhibit under the treatment history actually received. (ii)
No unmeasured confounder assumption (NUCA) implies that W C is independent of
Ak conditional on (Ok,Ak−1) for k = 1, · · · , K. (iii) The positivity assumption says
that Pr(Ak(g)|Ok(g),Ak−1(g)) ≥  > 0 for k = 1, · · · , K with probability 1 for an
arbitrary small positive constant ; it basically guarantees that in the counterfactual
world where everyone follows regime g, if there were patients with history ok and
ak−1 that would be assigned to treatment ak, then, in the observational world, there
must be some patients with the same history (ok and ak−1) who are observed to take
ak. Using these assumptions, we have pLCk (ak−1)|L
C
k−1(ak−2),R
C
k−1(ak−2)
(lk|lk−1, rk−1) =
pLk|Lk−1,Rk−1,Ak−1(lk|lk−1, rk−1,ak−1) and pRCk (ak−1)|LCk (ak−1),RCk−1(ak−2)(rk|lk, rk−1) =
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pRk|Lk,Rk−1,Ak−1(rk|lk, rk−1,ak−1), where p(·) denotes the probability function. There-
fore we are able to make inference about µb using only the observed data (AK−1,OK)
(see Section 3.7 for details of the proof).
3.3 Method
For most subjects in the observational data, we do not know if they are adhering to
a treatment regime, and if they are following a specific regime, we may not know what
that regime is, other than what can be inferred from the observed data. However,
we wish to estimate the specific survival experience that the whole cohort of subjects
would have had if they had truly been adherent to gb.
3.3.1 Inverse Probability of Adherence Weighting
We proceed by artificially censoring subjects at their first non-adherent visit. For
a specific regime gb, let Cbk = Akg
b
k(Ok)+(1−Ak){1−gbk(Ok)} be the indicator of ad-
herence at time k = 0, · · · , K−1, which is 1 if the patient’s observed treatment status
at time k is the same as if he is following regime gb (adherent), and is 0 if the observed
and regime gb specific treatment statuses are different. The patient would follow the
regime until time k if C
b
k = 1¯, where we use overbars to represent the history of a
covariate, for example, C
b
t = {Cbu; 0 ≤ u < t} is a subject’s adherence history up to
time t. 1¯ is a vector of 1’s the same length as C
b
k. The patient is censored at time
t = mintk{Cbk = 0 for k = 0, · · · , K} to generate the regime gb adherence dataset, i.e.
we only consider the time period when a patient’s observed treatment is consistent
with regime gb. Notice here, for a patient who partially follows the regime of interest,
we will include him in the regime gb adherence dataset, but only up to the first time
he stops to follow the regime.
In order to correctly estimate the regime gb specific counterfactual survival function
50
as well as µb, we propose to adjust for the bias induced from the artificial censoring
by weighting each subject by their Inverse Probability of Adherence Weights,
wbk =
I
(
C
b
k = 1¯
)
∏k
j=0 P
(
Cbj = 1|C
b
j−1 = 1¯,Oj = oj
) (3.2)
Briefly, at each time point, each adherent subject is weighted by the inverse of the
probability that they remained adherent given their measured covariate history, and
thus account for themselves as well as other similar subjects who were non-adherent
and artificially censored. Because we are considering discretized visits, the probability
of adherence for a patient at time k is then calculated as the multiplication of the
conditional probabilities of adherence at each time point j (j = 0, · · · , k) given that
he remained adherent up to time j − 1. For ease of notation, we define Cb−1 = 1 for
all patients. Following Robins (1993), in practice, we use the stabilized version of the
weights:
swbk =
k∏
j=0
P
(
Cbj = 1|C
b
j−1 = 1¯,L0 = l0
)
P
(
Cbj = 1|C
b
j−1 = 1¯,Oj = oj,Aj−1 = aj−1
) (3.3)
The model in the numerator includes only baseline covariates and serves to stabilize
(i.e. reduce the variability of) the weights.
3.3.2 Random Forest Regression
In order to make unbiased estimation based on these weights, it is important that
the model for adherence is correctly specified. Traditionally, the probability models
in the numerator and denominator of Equation (3.3) are estimated by fitting logistic
regression models to the pooled data from all possible pieces of person-times (Herna´n
et al., 2006). In our case, the regime rules are defined based on the PSA value, and
since the PSA has a non-linear relationship with time, it would be hard to expect
that a simple logistic regression model would capture the association between adher-
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ence and covariates. We propose to use Random Forest regression to model these
probablities.
Random Forests (Breiman, 2001) is a non-parametric classification and regression
method. It employs a combination of resampling and ensembles single tree based
models to give superior performance in both classification and regression. Compared
to the parametric logistic regression, it provides more flexibility without imposing
many structure assumptions. In detail, as the number of patients at risk decreases
over time, it may not be efficient to fit separate conditional probability models at each
time point. We proceed by pooling the data of all person-time pieces together to do
the Random Forest regression, while putting in time as a covariate to account for the
fact that these conditional probabilities vary over time. The numerator and denomi-
nator in Equation (3.3) will be modeled separately. For the denominator, we first fit
model for observed treatment assignment mechanism, P
(
Ak = 1|Ak−1 = 0¯,Ok = ok
)
with all the observed data available up to the first time point when the patient is on
treatment, i.e. person-time pieces up to tm with m = max{k : Ak−1 = 0, k ≤ K}
then the target probabilities can be calculated from
P
(
Cbk = 1|C
b
k−1 = 1¯,Ok = ok
)
=P
(
Ak = 1|Ak−1 = ak−1,Ok = ok
)
I{gbk(ok) = 1}
+ P
(
Ak = 0|Ak−1 = ak−1,Ok = ok
)
I{gbk(ok) = 0},
Since the treatment mechanism model for the observational data is the same regardless
of which regime is under investigation, this allows us to obtain the probability of
adherence for various regimes while only fitting the pooled Random Forest model
once. However, we may not be able to do the same thing for the numerator, as
it requires that this model should not be related to the time-dependent treatment
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status Aj−1. We proceed by directly fitting the model for regime specific adherence
mechanism P
(
Cbj = 1|C
b
j−1 = 1¯,L0 = l0
)
in the adherence cohort for each regime of
interest. More discussion on this issue can be found in Section 3.6. Here, the Random
Forest modeling is done using the R function randomForest with all default settings
except for the number of trees per forest and number of variables included at each
split, which we set at ntree = 1000 and mtry = 1. The adherence probabilities are
given from the “out-of-bag” prediction.
3.3.3 Weighted Nelson Aalen Estimator
To reduce the sample selection bias due to adherence, we assign a time-dependent
weight swbik for the ith subject at time tk, while his data are compatible with regime
gb under consideration, i = 1, · · · , N . Define the weighted number of events and the
weighted number at risk at time tk as
dbk =
∑
i:Ti=tk
swbikδ
b
i and Y
b
k =
∑
i:Ti≥tk
swbik
and then the formula that defines the weighted estimator for the regime gb-specific
survival function is Sˆb(t) = exp{−Λˆb(t)}, where Λˆb(t) = ∑tj≤t dbj/Y bj is the cumula-
tive hazard function. The estimated restricted mean survival time for regime g can
be calculated as µˆb =
∫ tk
0
Sˆb(t)dt. The optimal DTR is the one that maximize µˆb,
that is gˆopt = arg maxgb∈G µˆb.
3.3.4 Property of the Estimator
To derive the large-sample properties of µˆg(t), we need the following additional
regularity conditions. Specifically, we require for i = 1, · · · , N ,
(a) The observed data (Ai,K−1,Oi,K) are independent and identically distributed.
(b)
∫ τ
0
λb0(t)dt <∞ where λb0(t) is the true marginal hazard for any regime gb ∈ G.
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(c) For the true marginal survival function Sb0(t), we assume there exist continu-
ous first-order derivatives in t and bounded second partial derivatives (uniformly in
t ∈ (0, tK ]).
Along with the assumptions from Section 3.2, we can show that the proposed esti-
mator can give asymptotically consistent estimation to the counterfactual quantities
of interest. The main results are summarized in the following two theorems.
THEOREM 3.1 For any patient i = 1, · · · , n, and k = 1, · · · , K − 1, we have
P (Cbk = 1|C
b
k−1 = 1¯,Ok = ok) = P (Ak = 1|Ak−1 = ak−1,Ok = ok)I{gbk(ok) = 1}
+ P (Ak = 0|Ak−1 = ak−1,Ok = ok)I{gbk(ok) = 0}
The proof of Theorem 3.1 is outlined in Section 3.7. It connects the treatment model
and the model for the adherence to regime gb. So the weight calculated in Section
3.3.2 can consistently estimate the weight of adherence. Instead of directly modeling
the regime specific adherence mechanism for every regime, it only requires fitting one
model for all the regimes of interest.
THEOREM 3.2. Under assumption (i) - (iii) in Section 3.2 and the regularity
conditions (a) to (c), if the time dependent weights in Equation (3.3) are consistent
estimators of the true weights, then µˆb(t) converges almost surely and uniformly in
t ∈ (0, tK ] to µb0(t).
Theorem 3.2 assures that as long as the weights are correctly estimated, the pro-
posed weighted Nelson Aalen estimator will give a consistent estimate for the regime
specific survival function in the counterfactual world, and the estimation of the utility
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µb0 is also consistent. This establishes the consistency of the estimated optimal DTR
by maximizing µˆb(t) among gb ∈ G.
3.4 Simulation
In order to evaluate the performance of the proposed method, we conduct simula-
tion studies where we have access to the fully adherent data for each defined regimes,
and thus we can use these simulated counterfactual data to calculate the real causal
outcome when everyone follows the defined regime as the “gold standard”, and com-
pare it to the proposed estimator. To illustrate the role of flexible modeling in the
weight estimation, we compare the proposed method with an approach where the
weights are estimated from pooled logistic regression (Herna´n et al., 2006). In detail,
for the denominator of the weight in Equation (3.3), we will fit the treatment model
as
logit P
(
Ak = 1|Ak−1 = 0¯, O¯k = o¯k
)
= h1(k) + β1Ok + β
T
2V 0
and for the numerator, we fit the regime specific adherence model as
logit P
(
Cbj = 1|C
b
j−1 = 1¯,V 0 = v0
)
= h2(k) + β
T
3V 0
where we consider time-dependent intercept for both models, i.e. h1(k) and h2(k).
In the specific models below, Ok is the valure of log PSA measured at time tk, and
V 0 is the Tstage measured at baseline, in detail, we represent is as a 2-dimensional
vector V 0 = (I(Tstage = 2), I(Tstage ≥ 3))T . We use cubic spline with 2 internal
knots to estimate the intercept terms.
We consider two scenarios: (1) a simple case where the true treatment is assigned
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according to a logistic model, and (2) a more realistic model with a more complicated
PSA model and mechanism for treatment assignment. For each scenario, we simulate
500 datasets each with 2000 subjects, respectively.
3.4.1 Scenario 1:
We first present a case with a PSA model where the logarithm of PSA is linear in
time. The treatment would be generated such that it would be in favor of the pooled
logistic model. From now on, other than the time-dependent PSA, we also consider
the baseline covariate V0 as the baseline T-stage.
3.4.1.1 Longitudinal PSA Values
Let Pi(t) denote the observed PSA value, for subject i at t ∈ (0, tK ] years after
the start of follow-up (we choose tK = 15 year). We measure PSA every year at
t = 0, 1, · · · , 15, and the observed PSA values are simulated from the following linear
mixed model:
logPi(t) = logPSAi(t) + it = (α0 + ai0) + (α1 + ai1)t+ it (3.4)
where (α0, α1) = (−3.0, 0.3) are fixed effect parameters, (ai0, ai1) are subject-specific
random effects. At a given time t, we assume the measurement error it ∼ N(0, σ2)
where σ2 = 0.1, and we assume the random effects (ai0, ai1) ∼ MVN(0,Σ), where
Σ =
 1 0.5
0.5 0.25
. Here we also truncate ai1 at -0.1, such that the slope of log PSAi(t)
would not be negative, and treatment assignment according to the model below would
be clinically reasonable.
Note that, given the random effects, and in the absence of any treatment after time
t = 0, PSAi(t), which is referred to as the true PSA without treatment, is known and
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non-random. In contrast, the observed PSA value, Pi(t), are subject to measurement
error, and not observed after the earliest of salvage time or recurrence.
3.4.1.2 Different Treatment Regimes and Observed Treatment Time
For the counterfactual outcomes, we consider a finite number of dynamic SADT
treatment regimes as described in Definition (3.1). We consider 10 regimes with
{b1, b2, · · · , b10} = {−0.5, 0, · · · , 4.0}. Thus, according to subject i’s PSA trajectory,
we can calculate the regime specific time to initiate SADT as U b1i , U
b2
i , · · · , U b10i for
all 10 regimes. Here we assume that the observed treatment assignment for subject
i follows one of the above 10 regimes with the threshold value B, where B follows a
discrete uniform distribution for {b1, b2, · · · , b10}. The observed treatment time for
subject i is then Ui = U
B
i .
3.4.1.3 Model for Recurrence and Fully Compliant Data
For subject i with treatment initiation time Ui, we simulate recurrence times
according to a Cox model:
λi(t) = λ0 exp[θ
T
0V 0i + θ1logPSAi(t) + θ2logPSA
′
i(tk) + γi(t)I(t > Ui)] (3.5)
where λ0 = 0.2, θ0 = (0.2, 0.3)
T , θ1 = 0.3 and θ2 = 0. V 0i = (I(Tstagei =
2), I(Tstagei ≥ 3))T with patient i’s baseline T-stage sampled from {1, 2, 3, 4} with
probability p = (0.33, 0.59, 0.07, 0.01) (categorical distribution). The treatment effect
γi(t) =

min {[γi0 + β2(t− Ui)], 0} if γi0 < 0 and t > Ui
max {[γi0 − β2(t− Ui)], 0} if γi0 > 0 and t > Ui
0 otherwise
(3.6)
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where the initial treatment effect γi0 = β0 + β1logPSAi(Ui), with (β0, β1, β2) =
(−1.0,−0.4, 0.2). Thus, γi0 linearly depends on the logPSA value at the time of
treatment initiation, and then the magnitude of the treatment effect decays over
time, until it shrinks to zero. The survival function is
Si(t) = exp{−
t∫
0
λi(s)ds} (3.7)
and the survival time for subject i is then generated as T ∗i = S
−1
i (X), where X ∼
Uniform(0, 1), then T ∗i is rounded up to the closest visit time as Ti, or censored at 15
years as the study ends. Similarly, for each regime gbj , j = 1, · · · , 10, we can calculate
the survival time T
bj
i for subject i according to the counterfactual treatment initiation
time U
bj
i .
3.4.2 Scenario 2: More Complicated PSA Trajectory and Treatment
Model
Here, we consider a more realistic PSA model, and the treatment regimes in this
scenario are also set to be more complicated to mimic clinical practice.
3.4.2.1 PSA Models
In the absence of SADT, a typical trajectory of logPSA observed clinically would
have three phases (0: post-therapy, 1: short-term evolution, 2: long-term evolution).
Following Proust-Lima et al. (2008) and Taylor et al. (2013), for subject i at t ∈ (0, tK ]
years after the initial treatment, we simulate PSA values from the following mixed
model:
logPi(t) = logPSAi(t) + it
= (α0 + ai0) + (α11 +α
T
12V 0i + ai1)f(t) + (α21 +α22
TV 0i + ai2)t+ it
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where f(t) = (1 + t)−1.5 − 1 is used to model the short-term decreasing trend of
logPSA, and t is used to model the long-term increasing trend. (α0, α11,α12, α21,α22)
are fixed effect parameters, we take α0 = 1.0, α11 = 1.5, α12 = (0.2, 0.2)
T , α21 = 0.1,
and α22 = (0.2, 0.5)
T . (ai0, ai1, ai2) are subject-specific random effects, and V0i is the
vector of baseline T-stage indicators as in scenario 1. At a given time t, we assume
the measurement error it ∼ N(0, σ2) with σ2 = 0.2, and we assume the random
effects (ai0, ai1, ai2) ∼ MVN(0,Σ), where Σ =

1.0 1.0 0.15
1.0 2.6 0.45
0.15 0.45 0.5
.
3.4.2.2 Different Treatment Regimes and Observed Treatment Time
We consider 10 different regimes with {b1, b2, · · · , b10} = {−1.5,−1.0, · · · , 3.0}.
Thus, according to Definition (3.1), we can calculate the regime specific treatment
initiation times U b1i , U
b2
i , · · · , U b10i . The observed data are generated similarly as in
Scenario 1, but with more possible regimes, the observed treatment assignment for
subject i follows one of 100 regimes with the threshold value B, where B follows a
discrete uniform distribution for 100 evenly gapped values {−1.95,−1.90, · · · , 3.00}.
The observed treatment time for subject i is then Ui = U
B
i .
3.4.2.3 Model for Recurrence and Fully Compliant Data
We will use the same hazard model to generate the treatment with slightly different
parameter settings, i.e. for subject i with treatment initiation time Ui, the survival
time Ti will be generated from equation (3.5) (3.6) and (3.7) where λ0 = 0.15, θ0 =
(0.8, 0.9)T , θ1 = 0.1, θ2 = 0.1, β0 = 10.0, β1 = −10.0 and β2 = 0.2. Same models
are also used to define the counterfactual survival time T
bj
i for each regime g
bj , j =
1, · · · , 10.
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3.4.3 Simulation Results
Figure 3.1 shows the average Nelson Aalen survival curves in Scenario 1, where
we present one of the regimes (b10 = 2.0). As we can see without weighting, the
curve estimated from the adherent data without using weighting is biased from the
counterfactual fully adherent curve, so the weighted estimator is needed to give good
estimation for the counterfactual survival time. We can see both the pooled logis-
tic model and proposed method can effectively reduce the bias, while the proposed
method performs slightly better, we do see that the estimated curve in Figure 3.1a is
closer to the fully adherence curve. Similar results are also observed for other regimes
(data not shown).
In Scenario 2, the treatment is generated from a randomly selected regime and related
to the PSA trajectory which has a complicated shape. So it becomes difficult for the
pooled logistic method to correctly model the treatment assignment mechanism. As
shown in Figure 3.2, for regimes b4 = −1.0, the survival curve estimated by the pro-
posed method is almost the same as the counterfactual fully adherent curve, while
the curve estimated by the pooled logistic method shows notable bias to the truth.
For both scenarios, for any given b, we can calculate the true restricted mean survival
time, µg0(b) via Monte Carlo simulation with 10
6 replicates. Figure 3.3 gives µg0(b)
over different b for both scenarios. Figure 3.3a shows that for scenario 1, in the range
considered, µg0 is maximized at around b = −1.0 with µg0 = 7.13 year. Figure 3.3b
shows similar uni-modal relationship of µg0 and b, thus the optimal DTR would have
b = 1.5 which yields the maximum µg0 around 5.52 years.
Table 3.1 summarizes the estimated restricted mean survival time µˆ for the regimes
of interest. In both scenarios, the proposed estimator correctly identify the optimal
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regime, and the µˆ from the fully adherent cohort are close to µg0 in Figure 3.3. For
Scenario 1, µˆ from the unweighted dataset shows a monotone increasing trend as
the threshold b becomes larger. Both the pooled logistic method and the proposed
method recover the uni-modal trend and identify regime 7 with b7 = 2.5 as the op-
timal one that yields the maximal µˆ. This is consistent with the results from full
adherent data. For Scenario 2, although the unweighted estimator of µ also gives a
uni-modal shape over b, it gives the optimal regime as regime 6 while the true optimal
one is regime 7. As shown in the frequency of being identified as the optimal regime,
over the 500 simulations, 99.4% of them shows regime 7 is the true optimal regime,
while only 19.6% can correctly identify the optimal regime from the unweighted data.
By employing the weights, the pooled logistic method can correctly identify regime
7 as the optimal, but the bias to the µˆ for fully adherent data is also big. This
bias becomes much smaller for the proposed method. And comparing to the pooled
logistic method, the proposed method has much larger rate of identifying the right
regime as the optimal one (71.0% vs. 50.4%). Thus we can see introducing weights
can effectively reduce the bias when estimating the population survival outcome, and
the proposed flexible model can further help to correctly estimate the regime specific
outcomes in various scenarios.
3.5 Application to Real Prostate Cancer Data
We apply the proposed method to a multi-center prostate cancer study consisting
of 2,781 patients with clinically localized prostate cancer, all of whom were initially
treated with external beam radiation therapy (EBRT). In the dataset, PSA(ng/ml)
and T-stage were recorded prior to initial EBRT, with PSA monitored at periodic
visits throughout follow-up. A complete description of the data can be found in
Proust-Lima et al. (2008). In this analysis, we restrict attention to patients who
are being actively followed, and remove patients if the interval between adjacent PSA
61
measurements is more than 2 years. That gives a cohort of 2,427 patients. The longest
follow-up time was then 15.6 years. We also use the last observation carried forward
(LOCF) method to impute the missing PSA measures. There are 10.1% of the patients
who received SADT. We consider DTRs gb as defined earlier, where b is the cut-off for
the logarithm of (PSA+0.1). We consider regimes with b ranging from 0.7 to 4.2, i.e
{0.7, 0.8, · · · , 4.2}. This is chosen following a data adaptive manner. For each regime
under investigation, there are at least 3 patients who are fully adherent to the regime
and receive SADT during the course of study. The weights are estimated using
Random Forests for the probability of treatment/adherence with input covariates
PSA, slope of PSA, baseline T-stage and time t. Figure 3.4a shows that the regime
with b = 0.9 (2.36 ng/ml PSA) is identified as gopt by the proposed method, i.e. it will
be ideal to initiate SADT for patients with increasing PSA and first time has PSA
level above 2.36 ng/ml. The corresponding estimated restricted mean survival time
under this regime is µˆg =14.80 year. Figure 3.4b gives the weighted Nelson-Aalen
estimators for the optimal regime along with two other regimes.
3.6 Discussion
We show that the proposed method provides a powerful tool to identify the op-
timal DTR. Compared to other existing methods, our method possesses robustness
in two ways: for the adherence mechanism, the Random Forest regression allows us
to capture a large range of different treatment models, and for the survival outcome,
the non-parametric estimation also allows us to put less structure on the estimator.
Furthermore, the method is computationally feasible even for problems with rela-
tively large number of time points at which it is possible to initiate treatment. So
it is very useful in clinical studies and public health practice where the treatment or
intervention is made dynamically and needs to be optimized.
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In this chapter, we use the inverse probability weighting to correct for the selection
bias from the observational data with arbitrary censoring. We pooled the person-time
pieces from all time points to fit the model for adherence mechanism, since in most
real applications, there may be few individuals that are observed to follow a given
regime for a long time. Thus the adherence probability model at later time points
may become very unstable due to the limited availability of data. Pooling the data
across different time points can partially account for this problem, however, the tra-
ditional pooled logistic model may not always be satisfactory. Although allowing for
a time-dependent intercept h(t), it assumes the same linear dependence to covariates
over different time points. Employing Random Forest method to the pooled sample
may be preferable in this sense, as it automatically incorporates interactions between
time and other covariates, which allows the association between adherence probability
and covariates to vary over time.
In order to make the estimates more stable, we use the stabilized version of inverse
probability weights in this chapter. However, we may need to be cautious here as
the weights are now time-dependent, it is very important for us to make sure that
the numerator for swbi (t)’s are only models of baseline covariates. Cain et al. (2010)
has shown that the stabilization procedures commonly used for static regimes are not
valid for dynamic regimes. Here, we treat the models for numerator and denomina-
tor separately, the denominator model P (Cbt = 1|C
b
t−1 = 1¯, O¯t = o¯t,At−1 = at−1)
could be vary according to the treatment history At−1, while the numerator model
P (Cbt = 1|C
b
t−1 = 1¯,L0 = l0) and can calculated from the estimates of the treatment
model. P (At = 1|At−1 = 0¯,Ot = ot). While for the numerator, we need to fit model
for P (Ct = 1|Ct−1 = 1¯,L0 = l0), which do not restrict to person-time pieces when
At−1 = 0¯, so we choose to model the adherence Cbt directly.
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Pooled logistic regression has been a popular approach for estimating counterfactual
outcome distributions for time to event data when using IPW methods. Previous
literature has proved the equivalence of pooled logistic models and survival models
(D’Agostino et al., 1990). However, certain assumptions need to be satisfied to vali-
date the use of the pooled logistic model. Recent development in Random Survival
Forest has allowed the model to include time-varying covariates (Bou-Hamad et al.,
2011a) , and it would be interesting to employ this idea and directly fit a survival
model in the weight estimation. Compared to the current approaches, this could
further reduce the bias, while at the same time, provide more flexibility.
In the chapter, we try to make inference on the counterfactual outcomes from ob-
servational data. In practice, the estimation may only be consistent if the three basic
assumptions for causal inference are satisfied. The consistency assumption may be
the hardest one to verify. For the no unmeasured confounders assumption, it is very
important that we include all the covariates that could possibly affect the treatment
assignment and adherence, this would require thorough understanding of the problem
and sufficient communication with the clinicians and practitioners. The positivity as-
sumption would require that every patient should have a positive probability to follow
all regimes under consideration. This is an assumption that may also be hard to verify
in practice. One issue here is the number of treatment status or adherence status will
grow exponentially as the number of stages or visits increases. Consider a study with
visits at t = 1, · · · , K, then if we want to make inference on every possible regime
in AK = {0, 1}K , is would require that for any given OK = oK , the probability
of being in any one of the 2K status be positive. In practice, this would require a
very large sample to make sure that every status would have a notable chance to be
observed. For example, in Scenario 1 of our simulation, we consider K = 15, for a
fixed OK = oK , if every status was observed at least once, this would require more
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than 3 × 104 observations. This is also a problem in designing randomized trials to
identify optimal DTR. One possible solution is to impose some dependency structure
on the time series. For example, Markov assumption could be assumed such that
the current treatment/adherence status of a patient only depends on his/her treat-
ment/adherence status at previous time point, then the space of AK would reduce to
be linear with the increase of K. Thus overall the methodology does requires large
sample sizes and considerable heterogeneity in the patterns of treatment interaction
in the observational data. Without these modeling assumptions the uncertainty in
the results could be large. Meanwhile, the proposed method could also serve as a
preliminary analysis, which can find out which regimes in AK are estimable (viable)
in the given problem, then more accurate results could be obtained from randomized
trials that are designed based on only the set of viable regimes.
3.7 Appendix
3.7.1 The distribution of counterfactual and observational data
We demonstrate how to deduce the joint distribution p
O
C
k (aK−1)
(ok) and condi-
tional distributions
p
LCk (ak−1)|L
C
k−1(ak−2),R
C
k−1(ak−2)
(lk|lk−1, rk−1) and pRCk (ak−1)|LCk (ak−1),RCk−1(ak−2)(rk|lk, rk−1)
for a fixed ak−1 ∈ Ak−1, k = 1, · · · , K from the distribution of the observed data.
Then under the consistency and no unmeasured confounders assumptions, the joint
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density of (W C ,AK−1) is
pWC ,AK−1(w,aK−1) = pWC (w)pAK−1|WC (aK−1|w)
= pWC (w)pA0|WC (a0|w)
K−1∏
j=1
pAj |Aj−1,WC (aj|aj−1,w)
= pWC (w)pA0|L0(a0|l0)
K−1∏
j=1
pAj |Aj−1,Lj ,Rj(aj|aj−1, lj, rj)
Moreover,
pWC ,AK−1|AK−1,OK (w,aK−1|aK−1,oK)
=
pWC ,AK−1(w,aK−1)∫{
u:L
C
K(aK−1)=lK ,R
C
K(aK−1)=rK
} pWC ,AK−1(u,aK−1)dvWC (u)
=
pWC (w)pA0|L0(a0|l0)
∏K−1
j=1 pAj |Aj−1,Lj ,Rj(aj|aj−1, lj, rj)∫{
u:L
C
K(aK−1)=lK ,R
C
K(aK−1)=rK
} pWC (u)pA0|L0(a0|l0)∏K−1j=1 pAj |Aj−1,Lj ,Rj(aj|aj−1, lj, rj)dvWC (u)
=
pWC (w)∫{
u:L
C
K(aK−1)=lK ,R
C
K(aK−1)=rK
} pWC (u)dvWC (u)
=p
WC |OCK(aK−1)(w|oK)
Thus,
p
O
C
K(aK−1)
(oK) =
pWC (w)
p
WC |OCK(aK−1)(w|oK)
=
pWC ,AK−1(w,aK−1)
p
WC ,AK−1|AK−1,OCK(aK−1)(w,aK−1|aK−1,oK)
=
pWC ,AK−1(w,aK−1)
pA0|L0(a0|l0)
∏K−1
j=1 pAj |Aj−1,Lj ,Rj(aj|aj−1, lj, rj)pWC ,AK−1|AK−1,OCK(aK−1)(w,aK−1|aK−1,oK)
=pOK |OK−1,AK−1(oK |oK−1,aK−1)pL0(l0)
K−1∏
j=1
pOj |Oj−1,Aj−1(oj|oj−1,aj−1)
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LetW k =
{
L0,L
C
1 (a0), R
C
1 (a0), · · · ,LCk (ak−1), RCk (ak−1), ∀ak−1 ∈ Ak−1
}
, k = 1, · · · , K.
Using the same argument, pW k,Ak−1(w,ak−1) = pW k(wk)pA0|L0(a0|l0)
∏k−1
j=1 pAj |Aj−1,Oj(aj|aj−1,oj)
and p
O
C
k (ak−1)
(ok) = pL0(l0)
∏k
j=1 pOj |Oj−1,Aj−1(oj|oj−1,aj−1). It follows that
p
OCK(aK−1)|O
C
K−1(aK−2)
(oK |oK−1) =
p
O
C
K(aK−1)
(oK)
p
O
C
K−1(aK−2)
(oK−1)
=
pL0(l0)
∏k
j=1 pOj |Oj−1,Aj−1(oj|oj−1,aj−1)
pL0(l0)
∏k−1
j=1 pOj |Oj−1,Aj−1(oj|oj−1,aj−1)
= pOK |OK−1,AK−1(oK |oK−1,aK−1)
Similarly, for k = 2, · · · , K,
p
OCk (ak−1)|O
C
k−1(ak−2)
(ok|ok−1) = pOk|Ok−1,Ak−1(ok|ok−1,ak−1)
Furthermore, for k = 2, · · · , K
p
LCk (ak−1)|O
C
k−1(ak−2)
(lk|ok−1) = pLk|Ok−1,Ak−1(Lk|ok−1,ak−1)
and
p
RCk (ak−1)|O
C
k−1(ak−2),Lk(ak−1)
(rk|ok−1, lk) = pRk|Ok−1,Lk,Ak−1(rk|ok−1, lk,ak−1)
3.7.2 Proof of Theorem 3.1
For a given regime g, Ck = Akgk(Ok)+(1−Ak){1−gk(Ok)} for k = 0, · · · , K−1,
thus,
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(i) For the case that ak−1 = 0
P (Ck = 1|Ck−1 = 1¯,Ok = ok) =E
{
I(Ck = 1|Ck−1 = 1¯,Ok = ok)
}
=E
[
I
{
Akgk(Ok) + (1− Ak){1− gk(Ok) = 1|Ck−1 = 1¯,Ok = ok
}]
=E
[
I
{
Ak = 1|Ck−1 = 1¯,Ok = ok, g(ok) = 1
}]
I {g(ok) = 1}
+ E
[
I
{
Ak = 0|Ck−1 = 1¯,Ok = ok, g(ok) = 0
}]
I {g(ok) = 0}
=P
{
Ak = 1|Ak−1 = ak−1,Ok = ok
}
I {g(ok) = 1}
+ P
{
Ak = 0|Ak−1 = ak−1,Ok = ok
}
I {g(ok) = 0}
(ii) For the case that ak−1 = 1, we have P (Ck = 1|Ck−1 = 1¯,Ok = ok) = 1,
meanwhile,
P
{
Ak = 1|Ak−1 = ak−1,Ok = ok
}
I {g(ok) = 1}
+ P
{
Ak = 0|Ak−1 = ak−1,Ok = ok
}
I {g(ok) = 0}
=P
{
Ak = 1|Ak−1 = ak−1,Ok = ok
}
I {g(ok) = 1} = 1
Theorem 3.1 then follows by combining (i) and (ii).
3.7.3 Proof of Theorem 3.2
The strong consistency of µˆg(tK) can be proved by first proving the consistency of
Λˆg(t) for t ∈ (0, tK ]. For subject i, let Ti be the event time and Di be the censoring
time for subject i. Let Xi = min{Ti, Di} and δi = I(Ti ≥ Di). The observed event
counting process is defined as Ni(t) = δiI(Xi ≤ t), and denote the at risk indicator by
Yi(t) = I(Xi ≥ t). Let wˆi(t) and w0,i(t) be the estimated and true weight for subject
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i at time t, respectively. Then the weighted Nelson Aalen estimator is
Λˆg(t) =
1
n
n∑
i=1
t∫
0
wˆi(s)
n−1
∑n
i=1 Yi(s)wˆi(s)
dNi(s)
Let k = maxj{tj ≤ s}, using the fact that wˆi(s) →a.s. w0,i(s) as n → ∞, and
the Strong Law of Large Numbers (SLLN), one can obtain that n−1
∑n
i=1 Yi(s)wˆi(s)
converges almost surely to
E [Yi(s)w0,i(s)] = E
{
E
[
Yi(s)w0,i(s)|Ok,Ak
]}
= E
{
E
[
Yi(s)
I(Cik = 1|Ok,Ak)
Pr(Cik = 1|Ok,Ak)
|Ok,Ak
]}
= E
{
Pr(Cik = 1|Ok = ok,Ak = ak)
Pr(Cik = 1|Ok = ok,Ak = ak)
E
[
Yi(s)|Ok = ok,Ak = ak
]}
= E
{
E
[
Y Ci (s)|O
C
k (ak) = ok
]}
= E
[
Y Ci (s)
]
= Pr(DCi > s)S
g(s)
The second last equality holds by the results in Section 3.7.1. Using similar tech-
niques, one can show that n−1
∑n
i=1 wˆi(s)dNi(s) converges almost surely to Pr(D
C
i >
s)dF g(s) as n → ∞. The above listed results give Λˆg(t) a.s.→ Λg0(t). Therefore, µˆg(t)
converges to µg0(t) almost surely as n→∞ using the continuous mapping theorem.
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(a) Nelson-Aalen Estimator Using Logistic Model
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(b) Nelson-Aalen Estimator Using Proposed Method
Figure 3.1: The estimated survival curves for regime b = 2.0 in Scenario 1. In both
plots, the Nelson-Aalen estimators of the recurrence free survival are
plotted. The regime specific true curves (obtained from fully adherent
counterfactual cohort) are shown in dashed lines. The solid lines are for
the observational data (obtained by censoring subjects when they are no
longer adherent with the regime), and the dotted lines are the weighted
curves estimated by pooled logistic method (Figure 3.1(a)) or the pro-
posed method (Figure 3.1(b)). All curves are obtained by averaging over
500 simulations.
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(b) Nelson-Aalen Estimator Using Proposed Method
Figure 3.2: The Nelson-Aalen curves for regime b = −1.0 in Scenario 2. Similar as
in Figure 3.1, the regime specific true curves are shown in dashed lines.
The solid lines are for the observational data, and the dotted lines are the
curve estimated by pooled logistic method (Figure 3.2(a)) or the proposed
method (Figure 3.2(b)). All curves are obtained by averaging over 500
simulations.
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Figure 3.3: True µ under the two simulation Scenario 1 (Figure 3.3(a)) and Scenario
2 (Figure 3.3(b)). Each point in the plots above are calculated from 106
Monte Carlo samples.
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Figure 3.4: The survival estimation for the prostate cancer dataset. Panel (a) shows
the relationship between the restricted mean survival time estimated by
the proposed method µˆ and the logPSA threshold for SADT initiation
b. Panel (b) shows the weighted Nelson Aalen curves estimated for three
regimes, which includes the estimated optimal regime b = 0.9 (solid red
line), along with two other regimes b = 0.7 (dashed blue line) and b = 2.5
(dotted green line).
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CHAPTER IV
Identifying the Optimal Regime Using Random
Survival Forest with Weighted Bootstrap
In many biomedical studies, investigating the performance of different interven-
tions is a major goal, and in many cases, survival time is the primary outcome.
Patients with different characteristics are likely to respond differently to an interven-
tion. Thus, identifying the regime that defines who should receive which intervention
in order to provide most benefit to the whole population is often of great interest.
Recognizing treatment effect heterogeneity is essential in assigning the treatment to
patients who can really benefit from it. In this chapter, we consider data from ob-
servational studies where some of the covariates affect both the survival outcome and
the treatment assignment, while they may not all be available in the target popula-
tions. We propose to use Random Survival Forest (RSF) plus an inverse probability
weighted bootstrap to estimate the causal outcome while marginalizing over the un-
available covariates. Furthermore, by comparing the restricted mean survival times,
the optimal regime could be estimated for the target population based on the available
covariates. The proposed method (1) provides a flexible model structure to account
for the dependence of the survival outcome to the covariates, and (2) correctly esti-
mates the counterfactual outcomes for each treatment group. Simulations illustrate
that the proposed method performs reliably across a range of different scenarios.
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4.1 Introduction
It has been shown that patients can exhibit significant heterogeneity in response
to treatments in many different diseases (Ishigooka et al., 2000; Rothwell , 2005). The
emerging field of personalized medicine, which is focused on making treatment de-
cisions for an individual patient based on his/her own clinical, genomic, and other
information, has gained considerable interest, as it has the potential of maximizing
the treatment benefit for each person and hence for the whole population (Piquette-
Miller and Grant , 2007). Patients may be given a customized regime, with customized
dose or customized treatment schedule according to his/her prognostic or genomic in-
formation. The therapy may only be assigned to the patients at the dose that can
benefit that person the most, thus the optimal treatment effect could be achieved
on the population level without spending the extra resources that would be used if
everybody was treated with the same protocol.
Statistical approaches have been developed to find subgroups of patients who can
really benefit from the treatment under investigation in randomized clinical trials
(Foster et al., 2011). This task becomes more challenging when the outcome of pri-
mary interest is survival time, which may be censored (Kehl and Ulm, 2006), as is
common in phase III clinical trials. In practice, randomized trials are not always
available, thus methods to find the optimal regime from the observational data are
also needed(Qian and Murphy , 2011). In this chapter, we consider the case where the
data came from an observational study, with a censored time-to-event outcome. There
are two treatments, with treatment indicator A taking values either 0 or 1. Although
all covariates are measured at baseline (pretreatment) W = (X,Z), only a subset
of the covariates X is eligible to be candidates for constructing an optimal regime
which could be applied to other populations. The other covariates Z may also be
related to both the treatment assignment and the survival outcome. These variables
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may not be easy to obtain for the target population due to economic, logistical or
other reasons. For example, the covariate Z might measure health insurance, which
is not going to be relevant in the target population. The model of interest would
be only conditional on the covariates that are generalizable to the target population.
To enable the comparison between different treatment regimes, we adopt the causal
inference framework Rubin (1974, 1990), and the question then is how to correctly
estimate the mean for counterfactual outcomes conditional only on the covariates that
will be available. Those covariates that are not applicable to the target population
will need to be properly handled. A general approach in causal inference to adjust
for the confounding and estimate the causal effects is inverse probability weighting
(IPW), which has been widely used in survival analysis (Van der Laan and Robins ,
2003; Rotnitzky and Robins , 2005).
The optimal regime is a treatment decision rule depending on a region of the co-
variate space. One common approach in identifying the optimal regime is to propose
a linear combination of covariates, and if the linear combination is greater than a
threshold then one treatment is preferred and if the linear combination is less than
the threshold then the other treatment is preferred (Zhang et al., 2012). However, it
is very likely that the proposed space of optimal regimes does not include the truth,
and will thus lead to biased estimates. In this chapter, we propose to use a Random
Survival Forest (RSF) for the outcome model to provide the necessary flexibility in
modeling, and use inverse probability weighting to account for the confounders Z,
where the weighting is implemented using a weighted bootstrap procedure. Since we
are comparing survival outcomes under different counterfactual world, which have a
different amount of follow-up time, we propose to define the optimal regime as the
one that maximizes the restricted mean survival time. We introduce the notation
and some details of the proposed method in the next section. Section 4.3 contains
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results of simulation studies. We then conclude this chapter in Section 4.4 and some
technical details are given in Section 4.5.
4.2 Notation and Method
Consider a cohort of n patients from an observational study, let W i = (X
T
i ,Z
T
i )
T
denote a d-dimensional vector of baseline covariates for patient i, i = 1, · · · , n, where
X i is a d1-dimensional vector andZi is a d2-dimensional (d1+d2 = d). Ai = j, j = 0, 1
is the indicator for observed treatment status, with 1 for patients who receive the new
treatment, and 0 for patients who receive the standard treatment or no treatment.
For the outcome, let T 0i denote the survival time if subject i did not receive the
treatment, and T 1i denote the survival time if subject i receive the treatment. Let Ti
denote the actual survival time and Ci the censoring time, the observed outcome is
then (Yi,∆i) with Yi = min(Ti, Ci) and ∆i = I(Ti ≤ Ci). As in Chapter 3, we impose
the same three basic assumptions in causal inference:
1. Consistency assumption: Ti = AiT
1
i + (1− Ai)T 0i ;
2. Positivity assumption: 0 < P (Ai|W i) < 1;
3. No unmeasured confounders assumption (NUCA): T ai q Ai|W i, for a = 0, 1.
Note here that we are interested in the model for T conditional on X, so the above
is a slightly stronger version of the assumptions required here. In addition, we also
require the general assumption in survival analysis that T ai q Ci|W i, for a = 0, 1,
which will guarantee that Ti q Ci|W i. Since Xi is the vector that is available for
both the observed dataset and the target population, we are interested in deducing
the optimal regime that is based only on X i, which is denoted by g(X i) and takes
the values of either 0 or 1 specifying which treatment should be taken.
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4.2.1 Random Survival Forest
Machine learning algorithms have shown great potential in treatment heterogene-
ity and estimating optimal treatment regimes (Foster et al., 2011; Zhao et al., 2012).
Although for survival variables with censoring, the Cox proportional hazard regres-
sion model and its extensions are frequently used (Cox , 1972), survival tree based
methods have also been recognized as useful because of their flexible model structure
(LeBlanc and Crowley , 1995). A tree is grown by dividing patients at each node into
two groups, where the split is chosen to maximize certain criterion which measures
the survival difference. It thus has the advantage of automatically identifying certain
type of interaction without prespecifying the form of the interaction. The application
of ensemble methods provides a simple yet ingenious solution to the instability of
tree based methods (Bou-Hamad et al., 2011b). The Random Survival Forest (RSF)
is an ensemble tree method for analysis of right-censored survival data (Ishwaran
et al., 2008), which provides a flexible model structure that allows for complicated
interactions especially between covariates and treatment.
4.2.2 Inverse Probability Weighting
We propose to fit a logistic model for the probability of a patient receiving treat-
ment
logitP (Ai = 1|Li) = η0 + η1Li,
where Li is the vector of baseline covariates that will affect the treatment assignment.
Here, Li could have overlap with W i. In our case, we assume that Zi is a subset
of Li, and Li is a subset of W i. Thus, the treatment decision for patient i in the
observational data is made based on all or part of W i, which includes all Zi and all
or part of X i. Then the estimates pˆi = Pˆ (Ai = 1|Li) can be used to calculate the
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estimated weights as
wˆ1i =
I(Ai = 1)
pˆi
and wˆ0i =
I(Ai = 0)
1− pˆi ,
which reflects patient i’s estimated weights in the so-called treatment sample (wˆ1i )
and control sample (wˆ0i ), separately. Essentially, for those who are treated in the
observational data, they are weighted by 1/pˆi in the treatment sample, while weighted
by 0 in the control sample. For those who are not treated, they are weighted by 0 in
the treatment sample, while weighted by 1/(1− pˆi) in the control sample. With those
weights, we are able to create pseudo-samples that mimic the real counterfactual
world, it represent the whole population as if they were all treated in the same way,
and the models for counterfactual outcomes can thus be built from these pseudo-
samples.
4.2.3 Random Survival Forest in Weighted Bootstrap Samples
The goal is to build flexible models for the time to the event given X and A.
Random Survival Forest (RSF) is chosen here as it does not require much knowledge
about the underlying mechanism before model fitting (Ishwaran et al., 2008). We
will build separate models for the counterfactual outcomes of the treatment and of
control samples. One major challenge here is that the original algorithm of Random
Survival Forest does not consider weights for subjects, i.e. it assumes that every
subject contributes the same to the final model. In order to incorporate the weights
in the estimation procedure, we propose an additional layer of bootstrap sampling
prior to applying the Random Survival Forest method. We propose to first draw
a weighted bootstrap sample where the sampling probability for subject i is pro-
portional to its estimated treatment weight, i.e. wˆ1i /(
∑n
j=1 wˆ
1
j ), and the Random
Survival Forest models are then built on each sample as (Yi,∆i) ∼ X i +X2i , where
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X2i = {X21i, X22i, · · · } contains all the squared terms of X i. Thus for the Random
Survival Forest we allow both the covariates and their quadratic terms as inputs.
The inclusion of X2i as covariates is not essential, but in numerical work we found
that it commonly helps to improve the performance of the proposed method. The
final prediction is then obtained by combining the predictions over all the weighted
bootstrap samples. Several methods have been proposed to combine the results of
survival trees from bootstrap samples (Hothorn et al., 2004, 2006; Ishwaran et al.,
2008). Similar approaches can be employed to combine results from multiple survival
forests, we propose to calculate the cumulative hazard function (CHF) by averaging
all the CHFs from Random Survival Forest models from each weighted bootstrap
samples. In detail, we use the R function cforest() from the party package to build
the Random Survival Forests, then the treeresponse() function is used to obtain
the survival probabilities S1(m)(t) (Kaplan-Meier estimator) for the RSF model from
weighted bootstrap sample m, m = 1, · · · , B. The number of bootstrap samples is
set at B = 100. The survival estimate for the final model is obtained by averaging the
cumulative hazard function (CHF) at the same time point over the bootstrap sample
specific forests, i.e. the final survival function for the treatment group is estimated as
Sˆ1(t) = exp{− 1
B
B∑
m=1
− log Sˆ1(m)(t)}.
The counterfactual mean model for the control group can be built in a similar way,
where the weighted bootstrap sampling is done with sampling probability proportional
to subject i’s estimated weight of being not treated, i.e. wˆ0i /(
∑n
j=1 wˆ
0
j ). Then the
final survival function for the control group Sˆ0(t) is obtained using weighted bootstrap
samples.
Sˆ0(t) = exp{− 1
B
B∑
m=1
− log Sˆ0(m)(t)}.
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A variation of this combining step would be to pool all the terminal nodes which con-
tains subject i from all trees over all forests and all bootstrap samples, and calculate
the subject-specific final survival function from this pooled sample.
4.2.4 The Optimal Treatment Regime
To identify the optimal regime, ideally, we would like to find the regime which
gives the longest mean survival time E{T} for the population. However, due to the
censoring, we do not have that available, so we choose to compare the restricted mean
survival time µ = E{min(T, τ)} for some τ > 0, i.e. the optimal regime gopt would be
the one that gives the longest µ over the regime space G, gopt = arg maxg∈G µg, where
the arbitrary time τ is chosen to be the longest follow-up time. µg is the restricted
mean survival time corresponding to regime g, given by
µg = E{E{min(T g, τ)|X}} = E{E{min(g(X)T 1 + (1− g(X))T 0, τ)|X}}
= E{g(X)E{min(T 1, τ)|X}+ (1− g(X))E{min(T 0, τ)|X}}
= E{g(X)µ1(X) + (1− g(X))µ0(X)}
= E{µ0(X) + g(X)(µ1(X)− µ0(X))}
The optimal regime can then be written as gopt(X) = I(µ1(X) > µ0(X)), where
µ1(X) denotes the restricted mean survival time for the patients with X in the
counterfactual world where everyone received the treatment, and µ0(X) denotes the
restricted mean counterfactual survival time where they were all assigned to the
control group. Since we already have the estimated survival functions Sˆ1 and Sˆ0, the
estimated conditional restricted survival time for the counterfactual outcome from
the control and treatment groups can be calculated as
µˆ0(X) =
τ∫
0
Sˆ0(t)dt and µˆ1(X) =
τ∫
0
Sˆ1(t)dt.
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Only when µˆ1(X) is larger than µˆ0(X), should we assign the patient to be treated.
Otherwise, we would leave the patient alone and not treat the patient, as we would
expected mean survival to be higher in that situation. The optimal regime can then
be estimated as gˆopt(X) = I(µˆ1(X) > µˆ0(X)). Therefore, according to one patient’s
covariates X, we can customize the decision on whether this individual should be
treated or not.
4.3 Simulations
4.3.1 Other Methods
In order to assess the performance of our proposed method, we also consider three
other methods to compare. As a standard and simple method, we consider the regular
Cox model. We fit a Cox model (Yi,∆i) ∼X i+Ai+X i×Ai, and use the final model
to calculate Sˆ1i (t) = P (Ti > t|Ai = 1,X i) and Sˆ0i (t) = P (Ti > t|Ai = 0,X i). The
conditional restricted mean survival time and optimal regime are then calculated in
the same way as for the proposed method. Second, we consider a weighted version of
the Cox model, where we fit separate Cox models (Yi,∆i) ∼X i with weights wˆ1i and
wˆ0i . Furthermore, we also consider a standard Random Survival Forest procedure,
where we fit an RSF (Yi,∆i) with input covariates X i and Ai, and then calculate
Sˆ1i (t) and Sˆ
0
i (t) in a similar way as the unweighted Cox model method. If the actual
treatment group for subject i is j, then Sˆji (t) is obtained from the out-of-bag estimate
using the random forest, and Sˆ
(1−j)
i (t) is obtained by applying the random forest to
that person’s baseline covariates X i, with the opposite of the observed treatment
group indicator 1−j. Similar steps in estimating the optimal regime are then followed.
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4.3.2 Simulation Schemes
We consider a moderate dimensional X with d1 = 20 from independent N(0, 1),
and a scalar Z (d2 = 1), which is correlated with X, the treatment indicator is then
generated from a logistic model for logit(P (A = 1|X1, X2, Z)). We generate the two
counterfactual survival outcomes from lognormal distribution models of the general
form
log T 0 = α +XTβ + γZ + 0 (4.1)
log T 1 = α +XTβ + γZ + h(X, Z) + 1, (4.2)
where 0 and 1 are generated independently from N(0, σ
2), and the observed survival
time is T = AT 1 + (1−A)T 0. For simplicity, we only consider uniformly distributed
censoring time C ∼ Uniform(0, τ). Thus we observe time Y = min(T,C) and the
event indicator ∆ = I(T ≤ C). The true optimal regime depends on the form of
h(X, Z).
The regime of interest is only based on X. In order to identify the true optimal
regime, we need to calculate the true model conditional on X, which is obtained by
integrating out Z from equations (4.1) and (4.2). Also notice that we compare the
restricted mean survival time, so the choice of time limit τ may also influence the
optimal regime. More details about this issue can be found in the Appendix.
4.3.3 Different Scenarios
We will set-up two sets of simulations with different optimal treatment regime
settings. In the first set of simulations, we consider the model with d = 21 baseline
covariates where X1, · · · , X20 are i.i.d. normally distributed with mean 0 and variance
1, and Z is highly correlated to X2, and generated from Z|X2 = x2 ∼ N(x2, 1). For
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treatment assignment, we consider the logistic model
logitP (A = 1) = 1.0 + 0.5X1 − 1.5X2 + Z.
We generate the counterfactual survival outcome using a linear combination of X
and Z:
log T 0i = 0.3 + 0.5X1 + 0.5X2 + 1.1Z + i0
log T 1i = −0.9 + 0.3X1 + 2.5X21 + 1.0X2 + 0.3Z + i1,
where i0 and i1 are generated from independent N(0, 1). As shown in the Appendix,
the conditional mean can be expressed as
E(log T 0i |X1, · · · , X20) = 0.3 + 0.5X1 + 1.6X2
E(log T 1i |X1, · · · , X20) = −0.9 + 0.3X1 + 2.5X21 + 1.3X2.
The optimal regime would be to give the treatment when E(T 1i |X1, · · · , X20) >
E(T 0i |X1, · · · , X20). Note that because the optimal is based on the expected value
of T and not the expected value of log(T ), the optimal regime is similar to but not
exactly equals to 2.5X21 − 0.2X1 − 0.3X2 − 1.2 > 0. We consider censoring at a fixed
time, i.e. C = τ , with two different τ values chosen to give either 20% or 45% cen-
soring.
In the second set of simulations, we consider the same distribution for X1, · · · , X20
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and Z. For the treatment assignment, we consider the logistic model
logitP (A = 1) = 0.1− 0.5X1 − 0.5X2 + 2Z.
And we generate the counterfactual outcomes as follows:
log T 0i = 0.5− 0.2X1 + 0.3X2 + 0.5Z + i0
log T 1i = 0.5− 0.2X1 + 0.3X2 + 0.5Z + q(X1, X2) + i1,
where i0 and i1 are generated from N(0, 4). And we choose function q(X1, X2) =
−1+2.5·I(X1 > −0.5)·I(X2 < 0.5). It can be easily seen that, the true optimal regime
(as τ →∞) is then to give treatment to patients with X1 > −0.5 and X2 < 0.5. We
generate censoring time C ∼ uniform(0, τ), two τ values are chosen to create either
20% or 45% censoring.
4.3.4 Simulation Results
For each simulation setting, we generate observational data with n = 1000 pa-
tients, with 100 replicates. First, to evaluate the estimation of the optimal regime,
we compare the estimated regimes with the true optimal regime in each dataset, and
calculate the percentage of correctly predicted treatment assignment:
Rmatch =
1
n
n∑
i=1
I(gˆ(X i) = g
opt
0 (X i)),
where gˆ(·) is the optimal regime estimated by one of the methods under considera-
tion, and gopt0 (·) is the underlying true optimal regime. For each simulated dataset,
Rmatch measures the fraction of patients where gˆ and g
opt
0 agree. Table 4.1 shows the
mean and standard deviation of Rmatch. We can see that, in all the cases, RSF based
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methods tend to give more patients the “right treatment” than the Cox model based
methods. In both scenarios, the weighted methods tend to give better prediction
than the unweighted method in the same category. This provides some evidence that
the inverse probability weighting works in term of correcting the selection bias from
observational data. It is interesting that in all cases, although the model structure is
misspecified, the weighted Cox method shows slightly better prediction comparing to
the standard Cox model.
The optimal treatment regime should be able to benefit the whole population, so
we also study the performance of the estimated treatment regime from each method
through the regime g specific restricted population mean survival time:
µg = n−1
n∑
i=1
[g(X i)µ
0(X i) + {1− g(X i)}µ1(X i)].
This can be interpreted as the true population average when everybody in the cohort
follows regime g. A good regime will yield larger µg. From Table 4.2, we can see
that in all scenarios, the true optimal regime yields the largest µg, the fact that it
is bigger than the regime where everyone in the cohort is treated or everyone is not
treated, suggests that the personalized regimes do have some advantage under certain
circumstances. In both scenarios, the RSF based methods show larger µg than the
Cox model based methods, and among the RSF based methods, the proposed method
gives larger µg in all cases, suggesting that the weighted bootstrap can improve the
results for such observational studies.
In both scenarios, the true regime is based only on X1 and X2, and not the other 18
covariates. Thus we can also project the estimated optimal regime onto the (X1, X2)
plane, and look at how close the estimated optimal regime is to the truth on this
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plane. Figure 4.1 and 4.2 show the plots for the scenario 1 with 20% and 45% cen-
soring respectively, Figure 4.3 and 4.4 show the results for scenario 2 with 20% and
45% censoring respectively. In each figure, the combined results from pooling all 100
simulated datasets are plotted. We can see in both scenarios, both standard Cox
model and weighted Cox model tend to give a linear partition of the treatment deci-
sion, while for both RSF based methods, the partition looks close to the true optimal,
suggesting that the estimated treatment regimes for most of the patients are close
to their true optimal treatment assignment. For both scenarios, comparing to the
45% censoring cases, the regimes estimated from 20% censoring cases are closer to
the optimal plots, suggesting the proposed method will perform better with lower
censoring rates.
Table 4.1: The Percentage of Subjects Who Would Be Correctly Treated With The
Optimal Regime If They Followed The Estimated Optimal Regime. The
mean and standard deviation (in parentheses) over the 100 replicates are
recorded, separately. For each setting, 4 methods are compared, Cox:
standard Cox model; wCox: Cox model with inverse probability weighting;
RSF: standard RSF model; bsRSF: proposed method. For each method,
the mean and empirical standard error of MSDs and recorded.
Cox wCox RSF bsRSF
mean % (SD %) mean % (SD %) mean % (SD %) mean % (SD %)
Scenario 1
20% censoring 49.08 (1.75) 49.87 (1.61) 70.56 (5.74) 77.38 (3.19)
45% censoring 44.73 (1.65) 46.03 (1.88) 58.74 (5.78) 63.23 (4.84)
Scenario 2
20% censoring 62.68 (4.36) 63.53 (4.60) 68.51 (3.61) 72.58 (5.41)
45% censoring 61.83 (4.35) 61.07 (5.62) 62.20 (3.93) 67.52 (4.67)
4.4 Discussion
Identifying optimal treatment regime in personalized medicine is a very attrac-
tive idea as it maximizes the treatment effect at the population level while saving
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Figure 4.1: Cumulative Plot for Estimated Treatment Regime for Scenario 1 with
20% Censoring. In each plot, the estimated optimal treatment regime is
plotted by showing the treatment assignment for all patients over the 100
replicates. The red dots are the ones should receive treatment according
to the estimated regime, and green dots are the ones who should not be
treated. The plot on top left is the true optimal regime, the middle panel
on top is the optimal regime estimated from the standard Cox model,
the top right panel is the optimal regime estimated from the weighted
Cox model, the bottom left panel is the optimal regime estimated from
the standard RSF model, the middle panel at the bottom is the optimal
regime estimated from the proposed method.
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Figure 4.2: Cumulative Plot for Estimated Treatment Regime for Scenario 1 with
45% Censoring. Similarly, the estimated optimal treatment regime is
plotted by showing the treatment assignment for all patients over the 100
replicates. The red dots are the ones should receive treatment according
to the estimated regime, and green dots are the ones who should not be
treated. The plot on top left is the true optimal regime, the middle panel
on top is the optimal regime estimated from the standard Cox model,
the top right panel is the optimal regime estimated from the weighted
Cox model, the bottom left panel is the optimal regime estimated from
the standard RSF model, the middle panel at the bottom is the optimal
regime estimated from the proposed method.
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Figure 4.3: Cumulative Plot for Estimated Treatment Regime, Scenario 2 with 20%
Censoring. Similarly, the estimated optimal treatment regime is plotted
by showing the treatment assignment for all patients over the 100 repli-
cates. The red dots are the ones should receive treatment according to the
estimated regime, and green dots are the ones who should not be treated.
The plot on top left is the true optimal regime, the middle panel on top is
the optimal regime estimated from the standard Cox model, the top right
panel is the optimal regime estimated from the weighted Cox model, the
bottom left panel is the optimal regime estimated from the standard RSF
model, the middle panel at the bottom is the optimal regime estimated
from the proposed method.
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Figure 4.4: Cumulative Plot for Estimated Treatment Regime, Scenario 2 with 45%
Censoring. Similarly, the estimated optimal treatment regime is plotted
by showing the treatment assignment for all patients over the 100 repli-
cates. The red dots are the ones should receive treatment according to the
estimated regime, and green dots are the ones who should not be treated.
The plot on top left is the true optimal regime, the middle panel on top is
the optimal regime estimated from the standard Cox model, the top right
panel is the optimal regime estimated from the weighted Cox model, the
bottom left panel is the optimal regime estimated from the standard RSF
model, the middle panel at the bottom is the optimal regime estimated
from the proposed method.
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the resources that will otherwise be allocated to patients who do not response well
to the therapy. Even for normally distributed or binary outcome models, a lot of
existing methods for estimating the optimal regime have a potential problem as the
assumption about the regime space may not match the objective for optimization,
this could lead to severe bias even if the proposed space contains the true optimal
(Qian and Murphy , 2011; Zhang et al., 2012). So it is useful to have a flexible model
that does not restrict the space in which the optimal regime can lie. Tree based
methods provide very good tools in this case as they allow a very rich model for the
interaction between treatment and other covariates. Furthermore, RSF can also con-
trol the overfitting problem through its tree building processes. Similar to Random
Forest, RSF can select the importance of the variables, which would be considered
as a good feature as an optimal treatment regime is commonly more desirable if it
requires the measurement of less baseline covariates.
In the simulation study, we consider standard and inverse probability weighted Cox
model as alternatives to the RSF based methods, and show that the RSFs give better
performance. A possible reason for the inferior performance of the Cox models is that
they assume proportional hazards and linear combination of X’s, neither of which
is true. In practice, a user may consider other formulations within the Cox model
framework, which may be a better approximation to the underlying true model, and
thus may lead to better properties. However, the selection for the right Cox model
would usually be a rather arbitrary process and require extensive experimentation and
deep understanding of the underlying mechanism. On the other hand, the nature of
RSF methods makes them adaptable to various underlying mechanisms automatically.
Here, we incorporate the inverse probability weighting into the survival modeling
via a weighted bootstrap. It enables us to use existing RSF packages to facilitate the
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implementation of the proposed method in R. An alternative would be to directly
incorporate the inverse probability weights in the tree growing processes, and build
each tree on weighted bootstrap samples to form the forest. The proposed method
has two layers of bootstrap resampling, which introduces more randomness into the
model, and thus would be expected to have better performance numerically. Mean-
while, it should be straightforward to adopt the weighted bootstrap approach to other
machine learning methods, especially for the ones where weighted versions are not
defined or developed.
One possible extension here would be to consider time-dependent covariates, and
optimize not only who to give the treatment to but also when it should be given. The
so-called dynamic treatment regime optimization has also drawn a lot of attention of
statisticians (Herna´n et al., 2006; Robins et al., 2008; Orellana et al., 2010a,b; Wang
et al., 2012). Using a Random Survival Forest model with time-dependent covari-
ates would be a promising direction for the development of effective tools to identify
optimal dynamic treatment regimes from observational data.
4.5 Appendix: Some Technical Issues
4.5.1 Models Only Conditional on X
To identify the optimal regime, ideally, we would like to find the regime which
gives the longest conditional mean survival time E{T |X} for each subject. However,
due to the censoring, we choose to compare the restricted mean survival time µ =
E{min(T, τ)|X} for some τ > 0. Depend on the choice of τ , this may lead to a
slightly different conclusion than direct comparison of the conditional mean survival,
we will discuss this issue later. But the first step is to obtain the true marginal
models, which are only conditional on X. As the full model has both X and Z in it,
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some calculation will be needed in order to marginalize over Z. In order to work out
the formula for this, here, we will start with simple model where both X and Z are
both one dimensional, consider a lognormal model
log T = β0 + β1X + β2Z + 
where Z = ηX+2, X ∼ N(0, σ21), 2 ∼ N(0, σ22), and  ∼ N(0, σ20) are independently
distributed. Now the quantity of interest is the conditional restricted mean survival
µ = E{min(T, τ)|X}. As the first step we can have the conditional mean for log T as
E{log T |X = x} = β0 + (β1 + ηβ2)x
The conditional mean survival time is then
E{T |X = x} =
∫ ∫
eβ0+β1x+β2z+fz|x(z)f()dzd
=
∫ ∫
eβ0+(β1+ηβ2)x+β22+f2(2)f()d2d
= eβ0+(β1+ηβ2)x
∫
eβ22φ(2)d2
∫
eφ()d
where
∫
exφ(x)dx =
∫
ex
1
σ
√
2pi
e−
x2
σ2 dx = e
σ2
2
∫
eβxφ(x)dx =
∫
eβx
1
σ
√
2pi
e−
x2
σ2 dx =
∫
ey
1
σ
√
2pi
e
− y2
β2σ2
1
β
dy = e
β2σ2
2
thus
E{T |X = x} = eβ0+(β1+ηβ2)x+ 12 (β22σ22+σ20)
95
The restricted mean survival (conditional on W = (X,Z)T ) is:
E{min(T, τ)|X,Z} =
∞∫
0
min(t, τ)f(t)dt
=
τ∫
0
tf(t)dt+
∞∫
τ
τf(t)dt
=
τ∫
0
tf(t)dt+ τP (T > τ |X,Z)
=
(
eβ0+β1x+β2z+
1
2
σ20
)
Φ
(
log τ − (β0 + β1x+ β2z)− σ20
σ0
)
+ τΦ
(
(β0 + β1x+ β2z)− log τ
σ0
)
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Next, we can calculate the conditional restricted mean survival (only conditional on
X):
E{min(T, τ)|X = x} =
τ∫
0
tf(t)dt+
∞∫
τ
τf(t)dt
=
+∞∫
−∞
u∫
−∞
eβ0+(β1+ηβ2)x+β22+f()df(2)d2 + τ
+∞∫
−∞
∞∫
u
f()df(2)d2
=eβ0+(β1+ηβ2)x
+∞∫
−∞
eβ22
u∫
−∞
ef()df(2)d2 + τ
+∞∫
−∞
∞∫
u
f()df(2)d2
=eβ0+(β1+ηβ2)x
+∞∫
−∞
eβ22e
σ20
2 Φ(
u− σ20
σ0
)f(2)d2 + τ
+∞∫
−∞
Φ(− u
σ0
)f(2)d2
=eβ0+(β1+ηβ2)x+
σ20
2
+∞∫
−∞
eβ22Φ
(
log τ − β0 − (β1 + ηβ2)x− β22 − σ20
σ0
)
f2(2)d2
+ τ
+∞∫
−∞
Φ
(
− log τ − β0 − (β1 + ηβ2)x− β22
σ0
)
f2(2)d2
=eβ0+(β1+ηβ2)x+
σ20
2
+∞∫
−∞
eβ2σ2zΦ
(
log τ − β0 − (β1 + ηβ2)x− β2σ2z − σ20
σ0
)
φ(z)dz
+ τ
+∞∫
−∞
Φ
(
− log τ − β0 − (β1 + ηβ2)x− β2σ2z
σ0
)
φ(z)dz
where u = log τ − β0 − (β1 + ηβ2)x − β22, and the integral here do not gener-
ally have a closed form, in practice, we use Gaussian quadrature based on nor-
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mal distribution to numerically get the above quantity with the aid of function
gauss.quad.prob() in the statmod package in R. The conditional restricted mean
survival is then both a function of τ and X, so we will use notation µ0(τ,X) and
µ1(τ ;X) the survival outcome of interest for treated and untreated cases separately.
To facilitate the comparison among regimes recommended by different methods, we
will also calculate the empirical mean outcome given regime g(X), that is µg(τ) =
PX [µ0(τ ;X){1− g(X)}+ µ1(τ ;X)g(X)], which is the conditional restricted mean
survival time for the targeted population when the whole population follows a given
regime g.
4.5.2 The Choice of τ
As mentioned above, µ0(τ,X) and µ1(τ ;X) will also depend on the choice of
τ , to see this clearly, consider the case where the survival outcome for treated and
untreated are
log T 0 = β0 + β1X + β2Z + 0 and log T
1 = β0 + β1X + h(X) + β2Z + 1
where X and Z could be multi-dimensional. Then the optimal regime to give the
longest conditional mean survival would be to give the treatment when h(X) > 0
(provided 0 and 1 have same distribution). However, the difference between the
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restricted mean survivals is
µ1(τ ;X)− µ0(τ ;X)
=eβ0+x(β1+ηβ2)+h(x)+
σ20
2
×
+∞∫
−∞
eβ212Φ
(
log τ − β0 − (β1 + ηβ2)x− h(x)− β212
σ0
)
φ(12)d12
+ τ
+∞∫
−∞
Φ
(
− log τ − β0 − (β1 + ηβ2)x− h(x)− β212
σ0
)
φ(12)d12
− eβ0+(β1+ηβ2)x+σ
2
0
2
×
+∞∫
−∞
eβ202Φ
(
log τ − β0 − (β1 + ηβ2)x− β202
σ0
)
φ(02)d02
− τ
+∞∫
−∞
Φ
(
− log τ − β0 − (β1 + ηβ2)x− β202
σ0
)
φ(02)d02
=A+B
with
A =eβ0+(β1+ηβ2)x+
σ20
2
+∞∫
−∞
{
eh(x)Φ
(
log τ − β0 − (β1 + ηβ2)x− h(x)− β22
σ0
)
−Φ
(
log τ − β0 − (β1 + ηβ2)x− β22
σ0
)}
× eβ22φ(2)d2
B =τ
+∞∫
−∞
{
Φ
(
− log τ − β0 − (β1 + ηβ2)x− h(x)− β22
σ0
)
−Φ
(
− log τ − β0 − (β1 + ηβ2)x− β22
σ0
)}
φ(2)d2
we can see here, if τ → ∞, then µ1(τ ;X) = µ0(τ ;X) if and only if h(x) = 0. In
practice, people usually choose time to study end or the longest follow-up time, i.e.
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τ is always large, in such cases, approximately, the optimal regime is similar to give
the treatment when h(x) > 0.
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CHAPTER V
Discussion and Future Work
Understanding the effect of a treatment on survival time or time to a specific
event for patients is one of the central tasks in clinical and health care research.
The presence of time-varying covariates in such cases could add more complexity to
the problem. There would be both theoretical and numerical challenges to extend
existing methods into this area. Furthermore, there has been increasing interest in
investigating how the treatment interacts with other pretreatment characteristics and
thus to personalize the treatment according to these characteristics of each individual.
When the covariates are time-dependent, for example like PSA in the prostate cancer
recurrence study described in Chapter I, it is more difficult yet much more appealing
to develop a treatment regime that will make treatment decision based on the real
time monitored PSA values and optimize the outcome. In fact, the idea of tailoring
the treatment dynamically according to the time-varying covariates has a wide spec-
trum of application. For example, in treating advanced non-small cell lung cancer
(NSCLC), patients typically experience two or more lines of treatment, it would be
very useful to find the optimal dynamic treatment schedule that can improve survival
for patients (Socinski and Stinchcombe, 2007). In this dissertation, we focus on pro-
viding some insights to the current issues in this field.
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In Chapter II, we proposed an estimation procedure to efficiently estimate the co-
efficient for baseline covariates under a general form of survival problem when there
are mixed covariates (both time-dependent and time-independent). One direct appli-
cation is that this approach can be used to estimate the treatment effect on recurrence
free survival time for prostate cancer patients, when the hormone therapy is assigned
at baseline and confounding effect of PSA is cumulative over time. It is reasonable
to assume that the whole history of the time-dependent variable would impact the
risk at current time. In optimal dynamic treatment regime (DTR) identification,
the cumulative impact of the time-dependent variable may exist in both the time-
dependent treatment assignment mechanism and counterfactual survival outcomes.
Thus it may be more useful for a treatment regime to assign treatment based on the
whole trajectory of the time-dependent covariates at the current time.
Machine learning methods do not heavily rely on pre-specified assumptions about
the structure of the model, which is a desired feature when the underlying model
structure is not very well understood. Tree-based methods are increasingly popular
statistical tools since Breiman et al. (1984) introduced the classification and regres-
sion tree (CART) algorithm. The simplicity of the single tree based model gives the
prediction rules very straightforward interpretations, however, it often yields poor
prediction accuracy. The ideas of ensembles and randomization dramatically im-
prove prediction accuracy, and make the tree-based methods become more and more
popular in the research community. Among various ensemble tree-based algorithms,
Random Forest is one of the widely used approaches after Breiman (2001) introduce
its general framework. In Chapter III, we focus on employing Random Forest algo-
rithm in modeling complex treatment mechanism and further developing personalized
medicine from observational studies. We propose to model the time-dependent treat-
ment assignment by considering series of conditional probability models at each visit.
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The weights are then calculated as a cumulative product of probabilities. This is
a common approach for handling time-varying weights. Although it gains efficiency
by pooling conditional models at different time points together, it also forces these
models to have similar structure which may not be realistic. As mentioned in Chap-
ter III, we can directly model the time to treatment using tools for survival analysis,
especially Random Survival Forest will be a very attractive alternative as it does
not impose many assumptions. However, we may need to be cautious as we start to
consider treatment over continuous time, stronger assumptions may be necessary to
enable causal inference in such situations, for example, the positivity assumption. In
practice, it may also require much larger populations in order to get reasonable esti-
mation. On the other hand, it may be more straightforward to use RSF for discrete
survival time in modeling the treatment mechanism when there are limited number
of treatment stages.
In Chapter IV, we propose a modified version of Random Survival Forest method
which allows different subjects to contribute differently to the model by giving them
different weights. The weighted bootstrap procedure incorporates the inverse prob-
ability weights into the model to correct for the selection bias in the observational
data. Moreover, it also provides additional randomness to the Random Survival For-
est algorithm which is likely to improve the performance of the proposed method.
One other possible improvement may be to include higher order terms and interac-
tion terms of the covariates as input into the Random Forest procedure. Although,
in theory, Random Survival Forest can automatically model the interactions, it has
been shown in numerical work that the inclusion of extra terms like interaction or
quadratics may improve the properties of the method in some circumstances (Foster
et al., 2011). Our goal in Chapter IV is to identify the optimal regime in the case
when all covariates are measured pretreatment and at baseline, and the treatment
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is also assigned at time zero. We focus on improving the performance of the model-
ing for the counterfactual outcomes, so we assume the true model for the treatment
mechanism is known and can be correctly modeled. However, when the treatment
mechanism is not clear, we may need to model the probability of receiving treatment
non-parametrically. Meanwhile, variable selection would also be important as the
pool of candidate predictors for the treatment probability could be very large. In
such cases, machine learning methods similar to what we proposed in Chapter III
would be useful to model the treatment. A more challenging problem would be to
extend this approach to the optimal dynamic treatment regime (DTR) identifica-
tion, where the weights are time-varying. Methods need to developed to allow each
person-time piece to contribute differently when building the Random Survival Forest.
Random Forest, Random Survival Forest and their extensions provide very useful
tools in detecting optimal DTR from observational data. Their flexible model struc-
ture is helpful in learning the treatment and survival outcome especially when the
underlying mechanisms are not well understood. Meanwhile, the built-in variable
importance measure gives us a tool for automatic variable selection. This is impor-
tant since simple regimes with less covariates are preferable in practice. However,
the original Random Survival Forest (Ishwaran et al., 2008) and most of its variants
only work for the case when the covariates are time independent. The major chal-
lenge lies in how to define splits on time-dependent covariates. One strategy that
has been implemented replaced the time-varying covariate with a low-order polyno-
mial approximation (Segal , 1992). In particular, linear summaries have been used
where each time-varying covariate is first regressed against time within individuals.
The intercept and slope for each individual are then used as covariates. This would
highly depend on that the model assumption for the regression on the longitudinal
covariate is correct, and as the regression is subject specific, it also requires that there
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are enough observations per subject to make each regression accurate. Neither of the
requirement would be easily satisfied in practice. Recently, Bou-Hamad et al. (2011a)
proposed a new random survival forest method to accommodate simultaneously time-
varying covariates and time-varying effects. Their basic idea is to handle time-varying
covariates by decomposing each subject as subject-time pieces, or as they called them
pseudo-subjects, according to the splitting rules. So one subject can be split apart
across two children nodes. More work along this line can be done for covariates in
continuous time, as well as its application in finding optimal DTRs.
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